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ABSTRACT
MALDI MASS SPECTROMETRY IMAGING FOR THE DISCOVERY OF
PROSTATE CARCINOMA BIOMARKERS
Lisa Harris Cazares
Eastern Virginia Medical School and Old Dominion University, 2008
Director: Dr. O. John Semmes
The elucidation of new biological markers of prostate cancer (PCa) should aid in
the detection, and prognosis of this disease. Diagnostic decision making by pathologists
in prostate cancer is highly dependent on tissue morphology. The ability to localize
disease-specific molecular changes in tissue would help improve this critical pathology
decision making process. Direct profiling of proteins in tissue sections using MALDI
imaging mass spectrometry (MALDI-IMS) has the power to link molecular detail to
morphological and pathological changes, enhancing the ability to identify candidates for
new specific biomarkers. However, critical questions remain regarding the integration of
this technique with clinical decision making. To address these questions, and to
investigate the potential of MALDI-IMS for the diagnosis of prostate cancer, we have
used this approach to analyze prostate tissue for the determination of the cellular origins
of different protein signals to improve cancer detection and to identify specific protein
markers of PCa. We found that specific protein/ peptide expression changes correlated
with the presence or absence of prostate cancer as well as the presence of micrometastatic disease. Additionally, the over-expression of a single peptide (m/z = 4355) was
able to accurately define primary cancer tissue from adjacent normal tissue. Tandem
mass spectrometry analysis identified this peptide as a fragment of MEKK2, a member of
the MAP kinase signaling pathway. Validation of MEKK2 overexpression in moderately
differentiated PCa and prostate cancer cell lines was performed using

immunohistochemistry and Western Blot analysis. Classification algorithms using
specific ions differentially expressed in PCa tissue and a ROC cut-off value for the
normalized intensity of the MEKK2 fragment at m/z 4355 were used to classify a blinded
validation set. Finally, the optimization of sample processing in a new fixative which
preserves macromolecules has led to improved through-put of samples making MALDIIMS more compatible with current histological applications, facilitating its
implementation in a clinical setting. This study highlights the potential of MALDI-IMS
to define the molecular events involved in prostate tumorigenesis and demonstrates the
applicability of this approach to clinical diagnostics as an aid to pathological decision
making in prostate cancer.
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CHAPTER 1
INTRODUCTION

1.1 Molecular Pathology of Cancer
Tumors are classified by their site of origin and their appearance under a microscope.
The hallmarks of cancer diagnosis are variations in cell architecture and nuclear structure,
but no single histological feature is absolutely diagnostic of cancer. Considerable effort
has been invested over the years by pathologists in the standardization of the
morphological analysis and classification of tumors for the facilitation of scientific
research and more importantly, for patient diagnoses and prognoses. Molecular pathology
studies the origins of disease based on the characterization of acquired genetic mutations
and alterations of gene products. Defining the molecular mechanisms that give rise to the
cancer phenotype is believed to represent a critical step in developing methods of early
detection and effective therapeutic regimens for cancer patients. Over the last 20 years,
morphological analysis has benefitted from the biochemical, immunohistochemical, and
nucleic acid examination of tissue samples [1]. Pathology reports containing molecular
data of clinical relevance are now being generated in many tumor types. For example, the
reporting of breast carcinomas includes, in most instances, estrogen receptor status, and
Her2/Neu expression and amplification [2, 3]. Molecular techniques are slowly but surely
transitioning into the clinical arena making molecular diagnostics an integral part of
clinical practice.
A major challenge in cancer diagnosis and treatment is related to the fact that the
pathological features of a tumor and the protein expression of existing markers do not
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provide complete guidance and accuracy in patient risk assessment and treatment
response [4]. Additionally, histopathology, which guides treatment in many cancers,
often subcategorizes aggressiveness insufficiently in early stage tumors [5]. These
differences in outcome may relate, in part, to stochastic events, such as the time at which
a single cancer cell happens to undergo all of the steps necessary for successful
metastasis, or they may relate to factors that can be reasonably well understood at a
deterministic level such as a field affect.

The Cancer Field Effect
The field affect or the idea of field cancerization was first conceived by Slaughter
in a 1953 publication [6]. It is defined as an area surrounding transformed cells which
contains daughter cells exhibiting early genetic changes without changes in
histopathology. Field cancerization is now a well known and well documented process of
malignant transformation. Several studies have confirmed the importance of this
phenomenon in tumor development. In one such study, by measuring loss of
heterozygosity [7], Larson et al showed that at least one-third of biopsy samples from
head and neck squamous cell carcinoma have tumor-associated genetic alterations in the
macroscopically normal mucosa adjacent to the tumor [8]. Histopathological analysis had
failed to detect tumor cells in these margins. Thus the high recurrence rate of some
cancers may be explained by field cancerization. The molecular/genetic abnormalities in
the histopathology negative tumor margins may represent tumor cells invading and
metastasizing from the original primary tumor. The genetic defects that comprise the
genotypic features of cancerous growths may coexist in benign appearing cells adjacent

to the primary tumor and therefore cannot be assessed by conventional histopathological
techniques. The implication is that cancerization fields may remain after surgery of the
primary tumor and may subsequently develop into loco-regionally recurrent cancers.
Determining that histologically normal biopsy specimens possess molecular signatures of
cancer fields suggest either the tumor was missed by the biopsy procedure or that some
cells in the tissue are progressing towards malignancy. This would help to classify these
individual as high risk for recurrence, necessitating closer surveillance. Thus, the ability
to detect field cancerization by examining existing and new molecular markers would
greatly aid clinicians in the assessment of surgical margins as well as the evaluation of
pre-neoplastic processes.

Tumor Stroma Interactions
Homeostasis of normal organs such as the prostate or breast is maintained through
reciprocal interactions between epithelial cells and their surrounding stroma with minimal
proliferation of either cell type [9]. It is possible that, following genetic alteration to the
prostatic epithelium, signaling from the epithelium to the surrounding stromal
compartment becomes altered. This can cause the reacting stroma cells to receive an
"inductive cue" from tumor epithelium to undergo trans-differentiation, whereby
stromal fibroblasts adjacent to tumor epithelium convert both morphologically and
phenotypically to myofibroblasts [10, 11]. A consequence of such a transformation may
be a change in the local microenvironment from promoting epithelial homeostasis to
promoting epithelial mitogenesis. Fibroblasts are primarily responsible for the synthesis,
deposition, and remodeling of the extracellular matrix (ECM) as well as for the

production of many soluble factors that regulate cell proliferation, morphology, survival,
and apoptosis [12] .In the past fibroblasts have been thought to be passive participants in
the neoplastic transformation of tissues; however, recent data indicates that they play an
active role [13] and, in combination with inflammatory cells, can promote the neoplastic
programming of tissues by increasing epithelial proliferation and migration, potentially
enhancing the invasive potential of the genetically altered epithelial cell [14, 15].

Summary
The current "gene-centric" paradigm of cancer theorizes that once we understand all
the genetic aberrations associated with cancer we will be able to target them individually
and reverse their effects to treat and cure the disease [16]. This view has many
misconceptions and overlooks the importance of protein alterations in disease. First, due
to the dynamic nature of cancer, both the number and type of genetic alterations may
change over time. Furthermore, the number of genes is far fewer than the number of
proteins and there is only a moderate correlation between mRNA transcript levels and
protein abundance in most cells and tissues [17]. Many genes can be alternatively spliced
and mRNA editing is also quite common [18, 19]. Finally, post translational
modifications (PTMs) often change protein function and behavior significantly and the
diverse realm of these modifications encompasses many of the critical signaling events
which occur during neoplastic transformation [20].
As an important biological indicator of cancer status and physiological state of the
cell at a specific time, protein biomarkers represent powerful tools for monitoring the
course of cancer [21]. They can have tremendous therapeutic impact in clinical oncology,
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especially if the biomarker is detected before clinical symptoms [22]. Unfortunately,
despite enormous efforts, in only a few tumor types have relevant markers been
established that can be used for early diagnosis or improved therapy in cancer [23, 24].
The lack of a sensitive robust technology to detect the signatures of cancer cells from
minute quantities of available tissues or serum has significantly slowed the identification
of reliable biomarkers to accurately diagnose and predict the course of most types of
cancers [25, 26]. Thus, enhancements in the molecular profiling of early lesions using
appropriate control tissue will enable important pathways that predict disease progression
to be deciphered.

1.1.1

Prostate Cancer Development and Epidemiology
Prostate cancer (PCa) is one of the most common malignancies in the US and

over 98% of all prostate cancers are adenocarcinomas that arise from epithelial cells in
the acini or ducts of the prostate gland [27]. Microscopically PCa can be well, moderate
or poorly differentiated [28]. Despite the common occurrence, little is known about the
etiology of prostate cancer, and the natural history of the disease has not been fully
established. PCa is slow growing in many cases with a long phase in which it remains
undiscovered. In fact many tumors may never become clinically important [29]. The
relatively benign course of many tumors means that treatment might not be beneficial and
may actually do more harm than good.
Ageing is still the most significant risk factor in the development of prostate
cancer. More than 70% of all PCa cases are diagnosed in men over 65 [30]. Other
important factors are race and steroid hormones. According to a multiethnic cohort study,
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PCa incidence is highest in African American men with more than double the risk
compared to Caucasians [31]. However, some studies have suggested that black men who
receive active therapy for newly diagnosed prostate cancer are probably not at any greater
risk for disease recurrence than are white men with tumors of similar pathologic grade
and clinical stage who receive the same treatment [32]. Clinical studies show a similarity
in prostate cancer outcome when pathological stage is organ confined but a worse
outcome when disease is locally advanced or metastatic in African-American versus
European-American men [33]. Additionally, there is increasing genetic evidence that
suggests prostate cancer in African-American men may be more aggressive, especially
when it occurs in younger men [34].
Less than 10% of all prostate cancers are inherited, and most cases appear to be
sporadic [35]. Dietary, lifestyle-related and environmental factors such as chronic or
recurrent inflammation [36] have also been implicated in the initiation and promotion of
prostate cancer. The Western lifestyle diet consisting of higher intake of fat, meat and
dairy products may be responsible for an increase in PCa risk [37-40]. Most likely, the
pathogenesis of prostate cancer involves interplay between environmental and genetic
factors.
The growth and development of the prostate is dependent on androgens [41].
Ablation of androgens by surgical or medical castration is an effective strategy in the
treatment of advanced prostate cancer [42]. Moreover, men with congenital abnormalities
in androgen metabolism and those who undergo castration before puberty do not develop
prostate cancer [43]. The normal prostate contains three zones and a fibromuscular
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stromal compartment. Approximately 70% of all PCa cases arise in the peripheral zone,
10-20% in the transition zone, and 5-10% in the central zone [44].
The histopathological changes encompassing prostatic intraepithelial neoplasia
(PIN) are the most likely precursor to PCa [45]. PIN is defined as a non-invasive preneoplastic growth of the cells lining prostatic ducts and acini. Disruption of the basal cell
layer increases with increasing grades of PIN (in PCa there is complete loss of the basal
cell layer) [46] . PIN has been shown to co-exist with PCa in approximately 85% of all
prostate surgery specimens and it has been suggested that most patients with PIN
detected in a biopsy sample will develop prostate carcinoma within ten years [47, 48].
The prostate lesion described as proliferative inflammatory atrophy (PIA) has been
proposed as a precursor to PIN, a possible earlier step in prostate carcinogenesis [49].
Several studies have found frequent association of PIA with inflammatory processes [36],
suggesting that chronic inflammation may result in damage to epithelial cells and produce
proliferative lesions [50]. The chronic inflammatory microenvironment, characterized by
the accumulation of macrophages and lymphocytes, is extremely common in the tissue
stroma and epithelium of the prostate and may support both the initiation and progression
of prostate cancer. [51]. This inflammatory environment has also been associated with
benign lesions of the prostate known as cystic atrophy.

1.1.2 Prostate Cancer Detection and Morphology
Standard methods for diagnosis and the assessment of prognosis in PCa include
digital rectal exam (DRE), serum prostate specific antigen (PSA), and ultrasound directed
biopsies [42]. The discovery and widespread utilization of serum PSA monitoring for
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early detection has greatly changed the way prostate cancer is diagnosed and treated [52].
However, PSA lacks specificity as a screening tool for prostate cancer, and there is really
no lower limit of PSA that entirely excludes cancer [53]. Unfortunately, PSA and DRE
results alone cannot diagnose prostate cancer, but can only indicate further testing is
necessary. Thus clinical decision making in PCa places a significant burden on biopsy
results. Ultrasound guided needle biopsy is the standard for diagnosis however a negative
result does not exclude the presence of cancer [54]. Multiple biopsy cores (8-12) are
most often taken, but sampling and analytical variables account for many false negative
results [55]. In clinical practice, false negative results promote a need for repeat biopsies
which can delay diagnosis and treatment or unnecessarily subject cancer-free men to
repeat biopsies.
The Gleason grading system which has been widely adopted for PCa is a strong
predictor of outcome [56]. This grading system separates the architectural features of the
cancerous glands into 5 histological patterns of decreasing differentiation, pattern 1 being
the most differentiated and pattern 5 being the least differentiated (see Figure 1 for
details). The Gleason sum score is obtained by adding the dominating primary grade and
the next most common secondary grade. A major limitation of this grading system, and a
result of aggressive screening procedures, is that a majority of newly diagnosed prostate
cancer cases are Gleason grade 6 or 7 tumors. These moderately differentiated tumors can
either be indolent or aggressive [57] and there are no reliable molecular markers for the
determination of these subclasses. New methods and molecular markers to assist
pathologists in both diagnostic and prognostic decision making are needed to aid in the
detection and treatment of prostate cancer.
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Recent advances in molecular research enable us to understand the functions of many of
the protein products of oncogenes and tumor suppressor genes in great detail. However, a
set of characteristic alterations have not been identified in the development and
progression of PCa. This is partly due to the marked heterogeneity and multifocal nature
of prostate tumors [58].
A candidate tumor suppressor gene for prostate cancer is PTEN. This gene is
among the most commonly mutated tumor suppressor genes in human cancer and
encodes for a lipid phosphatase that cleaves 3-phosphorylated phosphoinositides and
functions as a negative regulator of phosphoinositol-3-kinase signaling [59]. Like many
other tumor suppressors, PTEN targets proteins in signaling pathways that regulate cell
growth and apoptosis in healthy tissue and contributes to cancer when dysfunctional. The
frequency of PTEN inactivation appears to increase during the progression of prostatic
cancer [60]. ETS factors (named for the oncogene: v-ets) represent one of the largest
families of transcriptional regulators and have known functional roles in many biological
processes [61]. ETS factors have oncogenic activity and their aberrant expression is
associated with many of the processes that lead to prostate cancer progression.
Essentially, the upregulation of ETS gene expression in prostate cancers appears to be
driven by chromosomal rearrangements leading to oncogenic gene fusion products.
Fusion transcripts have been observed to result from fusion of a prostate-specific
transmembrane protease serine 2 (TMPRSS2) gene with the oncogenic ETS transcription
factors [62, 63]. The TMPRSS2 gene encodes for a transmembrane-bound serine protease
that is highly localized to the prostate gland, and is overexpressed in neoplastic
epithelium and androgen regulated [64]. The most prevalent gene fusion in PCa is
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Gleason Grades 1 and 2:
•Closely resemble normal prostate
•Seldom occur in the general population
•Very pale glands which grow closely together.

Gleason Grade 3:
•Most common grade
•Considered well differentiated (like grades 1 and 2).
•Have a normal "gland unit0
•Invading of glands into the stroma is prominent
•Cells are dark and the glands have variable shapes.

Gleason Grade 4:
•Probably the most important grade
•Ifa lot of it is present, patient prognosis is worsened
•Big jump in loss of architecture.
•Disruption and loss ofthe normal gland unit
•Much experience is required forthis diagnosis
•Not all patterns are easily distinguished from grade 3.

Gleason Grade 5:
•Important grade, predicts step towards poor prognosis.
•Seldom seen in men whose PCa is diagnosed early.
•Variety of patterns, no evidence of gland units.
•Often called undifferentiated

Figure 1. Description ofthe Gleason Scoring Paradigm.
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TMPRSS2 with the ETS transcription family member ERG [65]. The TMPRSS2-ERG
fusion occurs in 50% of clinically localized PCa, making it one of the most common
somatic genomic alterations identified in a human malignancy [66, 67]. A recent study
found that the TMPRSS2-ERG fusion status has the biological effect of promoting
common morphological features found in prostate cancer [68]. This study was the first to
show a connection between molecular alterations and distinct phenotypic features in PCa.
Precedence for this finding can be found in several other tumor types. Breast cancer
associated with BRCA1 germline mutations often has a higher mitotic rates and larger
areas of tumor with continuous pushing margins [69]. Additionally, microsatellite
unstable colon cancer is characterized by poorly differentiated tumor cells with an
expanding growth pattern and pronounced increase in lymphocyte infiltration [70]. The
histological identification of a tumor phenotype associated with a specific genotype
establishes an important bridge between pathology and molecular analysis. If these
observations hold clinical significance, they will become relevant for patient care.

1.1.3 Prostate Cancer Prognosis and Treatment
Many of the clinically important predictive factors in prostate cancer are still
derived from a pathologist's examination of tissue specimens using light microscopy.
Morphology based prognostic markers in use today for PCa patient management include
tumor type, tumor grade, tumor stage, tumor volume and surgical margins [58]. The most
important clinical prognostic indicators of disease outcome in prostate cancer are pretherapy PSA level and Gleason score. Patients with localized PCa who have pretreatment PSA levels of less than 4ng/ml and Gleason scores of less than 4 have greater
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than 90% chance of disease free survival [71]. In contrast, patients with PSA levels of
greater than 20ng/ml and Gleason scores of more than 8 have a poor prognosis (less than
50% disease-free survival) [71]. For the patients with intermediate values of PSA and
Gleason scores, additional prognostic strategies are required to give an accurate
prediction of disease outcome. DNA ploidy in PCa has been studied extensively and
provides prognostic information independent of histological grade and tumor stage [72].
Recent studies have shown that angiogenic potential is a potent prognostic indicator for
patients with PCa and that the evaluation of endothelial growth factors is useful in
assessing the angiogenic phenotype in prostate tumors [73]. Moreover, the choice of
therapeutic interventions for PCa at the time of diagnosis is almost solely dependent on
clinical and pathologic staging based on morphology and the prediction of degree of
aggressiveness of the disease [74]. Clinically applicable prognostic markers are urgently
needed therefore to assist in prognosis and the selection of optimal therapy.
Treatment for PCa depends on the stage of the disease, the age of the patient, and
the presence of other medical conditions. To date, there are four major treatment options
for patients with localized PCa: radical prostatectomy, radiotherapy, hormone therapy
and watchful waiting [75]. If the cancer has spread outside the prostate, with lymph nodes
and bone being the most common sites for metastasis, the most common treatment is
surgical or chemical castration, to lower androgen levels, causing a reduction in tumor
growth and symptomatic relief [76]. In men older than 70 diagnosed with well or
moderately differentiated tumors and low PSA levels, the physician may elect to follow a
course of "watchful waiting," in which the patient returns frequently for check-ups.
Treatment occurs only if the man's condition worsens (i.e. PSA levels rise). In patients
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undergoing radical prostatectomy, post surgical detection of PSA is consistent with
recurrent or persistent disease [71]. It is important to remember that PSA is not only
elevated in prostate cancer, but in benign prostatic hyperplasia (BPH) and inflammatory
conditions of the prostate such as prostatitis [77]. New biomarkers to determine the
aggressiveness of tumors and metastatic potential should aid in the treatment decision
process for localized PCa.

1.1.4 Prostate Cancer Biomarkers
PSA is a glycoprotein and a serine protease produced by prostatic epithelial cells.
Normally, PSA is secreted into seminal fluid where it functions to digest the gel formed
by seminogelins and fibronectin after ejaculation [52]. Small amounts of PSA naturally
leak into the bloodstream, but when cancer is present there is increased leakage due to the
destruction of the basement membrane of the organ, setting up a "leaky prostate"[77].
PSA isolated from seminal plasma, was first described in 1971 [78, 79] and the first assay
for PSA in serum was developed in 1981 [80]. By 1999 PSA was adapted by urologists
as a marker for PCa detection. Today, PSA is the most widely used tumor marker in
urology [52]. Despite this acceptance, the PSA serum test, as mentioned above, lacks
specificity and sensitivity. About 70% of men with an elevated PSA will not have
detectable PCa at biopsy [54] and 20% of all men with a normal serum PSA levels have
clinically significant PCa [81].
Numerous new biomarkers for PCa have been reported, but only a few have been
used in a clinical setting [82]. For example, the gene PC A3, also known as DD3,
expresses a non-coding messenger RNA, and is markedly upregulated in cancerous
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prostate cells, being overexpressed in >95% clinical specimens [7]. No discreet
cytoplasmic protein results from PC A3 transcription, and the function of this gene is not
clearly defined at present [83]. The T-cell coregulatory ligand B7-H3 protein is overexpressed in prostate tumor cells, and is significantly associated with multiple adverse
prognostic features of PCa, including larger tumor volume, extra-prostatic spread, higher
Gleason score, seminal vesicle involvement, and positive surgical margins [84]. Another
tissue marker over-expressed in prostate cancer cells is alpha-methylacyl CoA racemase
(P504S). This enzyme catalyzes the conversion of (2R) alpha-methyl branched chain
fatty acyl CoAs to their (S) stereoisomers. Positive staining for alpha-methylacyl CoA
racemase can be used to support a diagnosis of cancer on prostate needle core biopsies
when the tumor focus in question is greater than 1mm in dimension [85]. Thus far,
racemase is the only new tissue biomarker of prostate cancer that has gained clinical
acceptance.

1.2 Proteomics and Mass Spectrometry
Although DNA is the information archive, proteins do all of the work of the cell.
Proteins closely reflect the ongoing local pathophysiology of diseased tissue and thereby
become candidates for diagnostic and prognostic biomarkers and add to the archive of
molecular changes of cancer found through genomic studies. Proteomics encompasses
the comprehensive identification and quantification of proteins specific to the
physiological state of a cell, tissue or organism. Instead of focusing on one particular
protein, most proteomic studies seek to investigate hundreds or even thousands of
proteins simultaneously in a single experiment by coupling newly developed proteomic
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strategies with modern mass spectrometry techniques. Proteome investigations are
focused on either expression proteomics, which analyses up- and downregulation of
protein levels, or on functional proteomics, aimed at identifying interacting proteins and
multiprotein complexes in order to unravel molecular functions and signaling pathways
[86]. A detailed understanding of proteins found to be differentially expressed in a
disease-specific fashion should offer great insight into the understanding of specific
pathogenic mechanisms.
The cancer proteome is an exceptionally complex biological sample containing
information on perhaps every biological process that takes place in cancer cells, cancer
tissue microenvironment, and cancer cell-host interaction. Cancer cells release protein
biomarkers into the extracellular fluid through secretion of intact or cleaved peptides or
presumably due to dying/apoptotic tumor cells. In addition, cancer-associated circulating
markers can be contributed by the tumor microenvironment of surrounding host cells
such as fibroblasts and macrophages [87]. Some of these products can end up in the
bloodstream and hence serve as potential serum biomarkers. Therefore, studying the
cancer proteome is the logical starting point for identifying diagnostic biomarkers and
therapeutic targets for cancer.
The main goal of the emerging field of clinical proteomics is the development of
robust, sensitive and specific methodologies for the detection of protein biomarkers or
biomarker patterns which will enable scientists and physicians to make reliable early
diagnosis and predication of tumor progression. Understanding the molecular basis of
tumor characteristics offers great promise for unraveling the complex molecular events of
tumorigenesis, as well as those that control clinically important tumor behaviors such as
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metastases. Oncoproteomic analysis therefore represents a more direct way of
investigating malignancy at the individual cancer patient level opening up a new era of
individualized therapy. Although proteomics has proven its promise for biomarker
discovery [26, 88, 89], further work is still required to enhance the performance and
reproducibility of established proteomic tools before they can be routinely used in clinical
laboratory.
As a technology-driven science, proteomics has benefited by the simultaneous
advancement of many related research areas. For example, the completion of the genomic
sequences of human and other species have provided the amino acid sequence of all the
potentially encoded proteins for those species [90]. The resulting genomic sequence
databases encompass a library of amino acid sequence information that is required for
proteomic study. The development of modern mass spectrometry (MS), especially
matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI)
[91, 92], has made it possible to ionize and examine the resulting spectra of large analytes
such as proteins without significant fragmentation.
MS instruments consist of at least two basic components: an ionization module and a
mass analyzer. The ionization component confers electrical charges to the molecules to
be analyzed, typically by adding protons, thus generating ions that can move in the
electromagnetic fields of the mass analyzer. Ion movement is dependent on the mass and
charge of the ion, and can be measured as mass over charge (m/z) ratio. Ions are detected
by a device which is able to count the number of ions which strike it for every m/z ratio.
Many improvements in MALDI and ESI mass spectrometers have allowed these
instruments to emerge as vital tools for protein identification, posttranslational

modification characterization, examination of protein expression patterns, elucidation of
protein-protein interactions and the determination of protein structure [93-96]. These
improvements offer levels of sensitivity and mass accuracy never before achieved. The
recent progress of proteomics has opened new avenues for cancer-related biomarker
discovery.

1.2.1

MALDI Mass Spectrometry
MALDI-MS was introduced in 1987-1988 by Karas et al. [97] and Tanaka et al

[98] and is an ideal tool to investigate complex protein mixtures. A schematic of MALDI
instrumentation is shown in Figure 2. MALDI utilizes a matrix, a small acidic aromatic
molecule that absorbs energy at the wavelength of the irradiating laser. The analyte
molecule is mixed with the matrix, deposited and allowed to dry on a support. During the
drying process, matrix-analyte co-crystals form. These crystals are then subjected to an
ultraviolet laser which is fired to induce desorption and simultaneous ionization of the
analyte. In the MALDI-Time-of-Flight (TOF) [99] platform, irradiation by laser pulses
produces short bursts of ions that are then accelerated through a flight tube by an
electrostatic field to a common kinetic energy [99]. If all the ions have the same kinetic
energy, the ions with low mass to charge ratio (m/z) travel faster than those with higher
m/z values, and are separated in the flight tube. The number of ions reaching the detector
at the end of the flight tube is recorded as relative intensity. The TOF mass spectrum is a
recording of the detector signal as a function of time. The time of flight for a molecule of
mass (m) and charge (z) to travel this distance is proportional to the square root of its m/z
value. Calibration is achieved by analyzing standards of known molecular weight.
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MALDI is considered a "soft" ionization method which does not cause fragmentation of
the sample ions. This soft ionization results predominantly in the generation of singly
charged ions regardless of the molecular mass, hence the spectra are relatively easy to
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Figure 2. Schematic of the components of a MALDI-TOF mass spectrometer.

interpret. If the TOF measurement is performed m the positive ion mode, a general mass
shift of+1 Da is observed for all ions. The mono-isotopic form of this ion type is denoted
[M+H]+ due to the ionization process in which a proton is exchanged from matrix to
analyte. MALDI-TOF-MS is used for detection and characterization of biomolecules,
such as proteins, peptides, oligosaccharides and oligonucleotides, with molecular masses
between 400 and 350,000 Da [100]. Use of reflectron technology enables much higher
resolution and mass accuracy for analyses of peptides in a narrower mlz range [101, 102].
The ideal sample preparation for MALDI would be a homogenous layer of small
matrix crystals containing a solid solution of the analyte. The matrix should not modify
or react with the analyte before laser irradiation. Further, it must be possible to dissolve
the matrix in the same solvent as the analyte in order to obtain proper mixing. Matrices
must also have low sublimation rates because the sample is introduced into a vacuum for
mass spectrometric analysis. Another necessary characteristic is a strong absorption
coefficient at the wavelength of the laser. The multiple roles played by the matrix in the
desorption and ionization of large analytes has lead to the optimum choice of matrices for
different molecular classes being empirically determined [103]. It has been reported that
sinapinic acid provides the best signals for higher molecular weight proteins, whereas acyano-4-hydroxycinnamic acid is more suitable for lower molecular weight peptides
[104].
The protein peaks in a MALDI mass spectrum constitute a pattern that can be
interrogated for differences arising from the presence of disease. To move beyond
expression patterns and obtain the identities of the components in these highly complex
mixtures, it is necessary to use different mass spectrometry techniques for protein

identification. A protein can often be unambiguously identified by the accurate mass
analysis of its constituent peptides (produced by either chemical or enzymatic treatment
of the sample). Tandem mass spectrometry experiments (MS/MS), previously allowed
only with quadrupole and ion trap mass spectrometers are now attainable with MALDI
sources [105]. In MALDI-MS/MS experiments, protein identification is facilitated by
analysis of peptide fragment ions generated inside the MALDI mass spectrometer. In a
process known as collision-induced dissociation (CID), ions desorbed from the MALDI
support or target are accelerated through the first TOF region and precursor ion selection
is performed by a timed gate prior to CID in a gas (usually helium) filled collision cell
[106]. When the gas is introduced into the collision cell, the collision of the peptide
molecules with the gas molecules causes the formation of cleavage products. As seen in
Figure 3, product ions resulting from backbone cleavage of the aC-C, the C-N amide
linkage, or the N-aC bond are called a-, b-, and c-type ions respectively if the charge is
retained on the amino terminal fragment, or x-, y-, and z-type ions respectively if the
charge is retained on the carboxy-terminal fragment [107]. The most common ions types
formed by MALDI-TOF MS/MS analysis are a-, b- and y- ions. The product ions are
numbered according to their position from their respective terminal end. Therefore the
amino acid sequence and subsequent identification of a parent ion can be determined by
the deconvolution of the fragments present in the MS/MS spectra ("de-novo
sequencing"). Computer algorithms such as SEQUEST or MASCOT can then be used to
determine the "best fit" between the MS/MS sequence information and protein databases.
Another method for protein fragmentation in a MALDI-TOF-MS, termed "LIFT",
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example peptide with three residue peptide chain. The most commonly observed ions are
a, b, and y.
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allows for metastable fragmentation induced by a nitrogen laser without the use of
collision gas [108]. Selection of the target or parent species is first performed by a
precursor ion selector that works as a mass filter for the parent ion and fragments. A
relatively low voltage is applied initially for ion acceleration. Fragments are then
generated from laser-induced dissociation and subsequently LIFTed to a higher potential
energy in the LIFT cell. This enables the rapid (seconds) detection of all fragments
simultaneously. LIFT is particularly advantageous for the detection of low mass ions of
low abundance.

1.2.2

Electrospray Mass Spectrometry
Electrospray Ionization mass spectrometry (ESI-MS) was developed by Fenn et
al., in the early 1980's but was largely ignored until 1989 when Fenn showed spectra of
ionized proteins as large as 40,000 Da [91]. In 2002, Fenn was a Nobel Prize recipient for
his contributions to the analysis of biological macromolecules. ESI-MS allows for large,
non-volatile molecules to be analyzed directly from the liquid phase, whereas MALDI
analyzes samples from a solid state. ESI uses electrical energy to assist the transfer of
ions from solution into the gaseous phase before they are subjected to mass spectrometric
analysis. Within an ESI source, a continuous stream of sample solution is passed through
a stainless steel or quartz silica capillary, maintained at a high voltage. A mist of highly
charged droplets with the same polarity as the capillary voltage is generated. The solvent
surrounding individual droplets evaporates rapidly in the vacuum chamber of the
instrument, leaving unfragmented protein molecules which carry multiple positive
charges. These charged molecules are accelerated by an electric field and then deflected

by a magnetic field. They are then separated according to their m/z, commonly with an
ion-trap or quadrupole analyzer. A single protein or peptide will show its characteristic
cluster peaks containing multiple-charged ions. The number of charges on the molecules
will depend on the molecular weight of the protein or peptide and the number of
accessible basic sites (e.g. arginine, histidine, and lysine) [109]. Spectrum deconvolution
takes all the multiply charged ions and converts them into a spectrum on a mass (Da)
scale, working out what the molecular weight of the singly charged molecule is most
likely to be. To obtain structural and sequencing information, the precursor ions of
interest can be mass selected and further fragmented in a collision cell. The fragment ions
can then be mass analyzed by a second mass analyzer of a tandem mass spectrometer
system [110]. Since ESI mass spectra depends on the generation of ions in an aerosol, ion
formation is a competitive process. Therefore, salts, phosphate and sulfate buffers,
detergents and polyethylene glycols all compete for the charges. The presence of such
contaminants will result in poor quality spectra. In contrast, MALDI-TOF-MS is much
[107] more tolerant to the presence of salts and detergents [111].

1.3 Proteomic Methods for Cancer Biomarker Discovery using Tissue
From work already published, it is clear that the integration of MS into disease
diagnosis as well as outcome prediction will soon take place [112]. For example, recently
discovered protein markers in serum and other body fluids derived from MALDI-MS
proteomic studies have potential for diagnostic and prognostic applications in many
different disease types including cancer [113-118]. Most of these studies employ a
strategy of mining serum for biomarkers. This poses many challenges since abundant
serum proteins make it necessary to fractionate and/or deplete the serum in order to see
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proteins which may in fact be seeping into the blood from tumor sites. Using tissue as a
starting material for the discovery of biomarkers is attractive because that is where the
proteins originate. Unfortunately, tissue proteomics poses great challenges for traditional
proteomic approaches because of the heterogeneous nature of most tissues. Tissues are
complicated three-dimensional structures composed of multiple subpopulations of cells
interacting with each other and with the extracellular matrix. The situation becomes even
more complicated as pre-neoplastic and neoplastic lesions develop. For example,
histological inspection of prostate cancer tissue typically reveals a juxtaposition of benign
glands, preneoplastic (PIN) foci, and neoplastic foci of varying severity [119].
Overcoming these challenges is of the utmost importance since examining the protein
distributions in specific tissues is crucial to unraveling biochemical pathways and for the
diagnosis of many diseases.
There are two common approaches for proteome analysis in tissue samples: intact
protein separation and peptide separation. Protein separation methods include one- and
two-dimensional gel electrophoresis (1-DE and 2-DE), one- and two-dimensional liquid
chromatography (ID LC and 2D LC), and affinity chromatography for selective isolation
of a target protein [93]. Peptide separation is more limited and includes multidimensional
liquid chromatography and selective enrichment of a subset of peptides which is highly
representative of the parent proteins [120].

1.3.1 2D Electrophoresis
Traditionally, proteomic techniques aimed at biomarker discovery have centered
on the identification of differentially expressed proteins from cell or tissue samples

following gel or liquid chromatographic separation. Two-dimensional polyacrylamide gel
electrophoresis (2D-PAGE) is one of the most widely used techniques for proteomic
studies and can resolve thousands of different protein species [24]. Protein mixtures
derived from tissue lysates are first separated according to their isoelectric point by
isoelectric focusing and then separated according to their size by sodium dodecyl sulfate
(SDS-PAGE). The separated proteins are visualized with different staining techniques,
such as coomassie blue or silver. For expression proteomic studies, differentially
expressed proteins are identified by comparing spot intensities between samples. The gel
spots of interested can then be excised and digested with a protease for identification
using MS methods such as peptide map fingerprinting, and/or tandem MS [121]. The
quantification of proteins has now become more accurate with the introduction of highly
sensitive fluorescent stains or dyes with a wide dynamic range. These dyes have been
effectively employed in differential gel electrophoresis or DiGE [122]. In DiGE, the
protein samples to be compared are covalently labeled with a green or red fluorescent
dye. A mixture of both the samples is also labeled with a blue dye and serves as an
internal standard. All three samples are then mixed together and separated by 2D-PAGE.
The excitation and emission wavelengths of each respective dye are different, enabling
the visualization of different images of the protein spots attributed to each sample when
the gel is scanned .
Advances in 2D-PAGE technology coupled with robotics and software programs
for identifying potential protein alterations have improved this proteomic methodology.
Nevertheless, 2D-PAGE is still cumbersome, labor intensive, and suffers reproducibility
problems. Additionally 2D-PAGE requires large amounts of starting material (40-100 jug

of total protein to generate -500 spots/gel) to visualize adequate number of silver-stained
proteins in the gel [123], making it a poor choice for small clinical tissue samples or
biopsies. Furthermore, very acidic or basic proteins, very large or small proteins, and
membrane proteins are all underrepresented in 2D PAGE analysis [124].
Methods such as laser capture microdissection (LCM) have been used with great
success to select homogeneous cell populations [125]. LCM entails placing a transparent
film over a tissue section or a cytological sample, visualizing the cells microscopically,
and selectively adhering the cells of interest to the film with a focused pulse from an
infrared laser [126]. LCM combined with 2D-PAGE and more recently MALDI-MS, has
great applications in a wide range of biological systems. LCM's unique ability to quickly
and accurately generate protein profiles from small numbers of pure cells from a
heterogeneous tissue has extraordinary utility in finding disease markers, elucidating
mechanisms of tumor development, and classifying tissue subtypes by protein expression
levels [127-129]. However, the LCM technique cannot be easily applied to traditional
proteomic analysis because 50,000 to 100,000 cells are required for one 2D-PAGE
experiment [130]. Obtaining this large amount of cells manually is very labor-intensive,
and cannot be done routinely which limits any high throughput analysis. Taken together
the use of LCM followed by 2D-PAGE for any clinical proteomics study is difficult at
best and generally not feasible.
1.3.2 Chromotography Techniques
Alternative strategies to 2D-PAGE for cell and tissue proteome analysis are
generally based on increasing levels of protein and peptide separation coupled with
amino acid sequence analysis by tandem MS. One-dimensional liquid chromatography
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(1D-LC) can be used to separate proteins based on their size (mass), pi (charge), or
hydrophobicity. The most commonly used ID LC method is reverse phase
chromatography, which separates proteins based on their hydrophobicity. In proteomic
studies, ID LC has been used primarily for peptide separation before MS analysis, but it
can also be used for protein separation of complex lysates from cells or tissue before
enzymatic digestion and MS [131]. In two dimensional liquid chromatography (2D-LC),
proteins are separated in the first dimension by isoelectric chromatography (pi) (or SCXstrong cation exchange chromatography) and in the second dimension by hydrophobicity
(reversed phase) [132], thereby increasing the degree of protein fractionation and
decreasing sample complexity.
LC-MS has evolved into a powerful procedure for detailed identification as well
as quantification of complex proteomic samples offering the possibility to isolate and
sequence hundreds of selected peptides from one sample. Increasingly, proteomic
investigators are employing a strategy based on proteolysis of proteins followed by
analysis of the complex peptide mixture by LC-MS/MS. This approach is referred to as
"shotgun" or multidimensional protein identification technology- i.e. "MudPIT" and was
first described by Yates and co-workers [133]. Typical MudPIT approaches use SCX
followed by reverse phase chromatography interfacing directly with ESI-MS,
dramatically cutting down on analysis time. Recently this MudPit approach was applied
to analyze the global proteome of the KATO III human gastric carcinoma cell line. This
analysis led to the identification of 1966 uniquely expressed proteins contributing to the
characterization of human gastric carcinoma [134]. A caveat to this type of analysis
should be mentioned. Since samples must be initially digested with trypsin or another
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protease before analysis, this results in a vast increase in complexity of the results making
it more difficult to unambiguously reassemble peptide sequences into their precursor
proteins. This is especially true in higher eukaryotic organisms, because a single distinct
peptide sequence can be represented in several distinct biologically active protein
isoforms.

1.3.3 Protein Arrays
Traditionally, immunohistochemistry (IHC) has been a technique commonly used
for profiling protein distributions in tissue. In this approach antibodies are needed to
detect specific proteins and usually only one protein can be detected in a single
experiment. The use of protein arrays can facilitate the detection of multiple proteins in a
single experiment. A protein microarray consists of antibodies, proteins, protein
fragments, peptides, aptamers or carbohydrate elements that are coated or immobilized in
a grid-like pattern on small surfaces. There are mainly two types of protein microarrays:
analytical and functional [135, 136]. Analytical or detection protein microarrays are used
to profile and quantitate antibodies or proteins, and frequently consist of antibodies
directed against a defined set of proteins from cells or tissues [137]. These antibodies are
robotically spotted onto a solid support such as a glass slide. The slides are then probed
with cell or tissue lysates. In contrast to MS pattern analysis, protein microarrays start
with a limited, but specific, knowledge of the identities of important signaling molecules
in the cancer cell. With protein microarrays it is possible to measure the activated (e.g.,
phosphorylated or cleaved) form of key signal proteins and thereby estimate whether the
designated signal node is "in use" at the time the proteins are extracted from the cell. The
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greatest challenge in the use of antibody arrays is obtaining antibodies against all the
proteins that comprise the human proteome. At this time antibodies are available for a
mere fraction of the proteome. Reverse-phase protein microarrays, are based on the
opposite configuration from an antibody array. Cellular proteins (nano or pico liter
amounts) to be assessed are robotically spotted onto a nitrocellulose backed slide.
Subsequently, each slide can be probed with an antibody that can be detected by
fluorescent, colorimetric or chemiluminescent assays. The signal intensity of each array
spot is proportional to the concentration of the analyte member within the population of
proteins immobilized on the spot. Relative quantitative comparisons of protein
concentrations can be made within or between multiple study cases. Investigations
performed by Paweletz, et al. demonstrate the utility of reverse phase protein arrays to
monitor proteins expressed during disease progression [138]. Protein arrays technologies
may uncover molecules with specific post translational modifications differentially
expressed in a disease state, but primarily they are used for the validation and
quantitation of existing biomarkers. They are therefore not useful tools in the discovery
of novel markers. Furthermore, the expression and analysis of proteins is carried out in
artificial environments relative to the cell and these environments may not have
physiological relevance to the biological system under study.

1.3.4

New Methods for Tissue Proteomics and Biomarker Discovery.

A major shortcoming associated with the early detection and treatment of cancer is the
lack of sensitive and robust technology to detect the molecular signatures of cancer cells
from minute quantities of available tissues or serum. New methodologies for tissue
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protein profiling such as LCM combined with MALDI mass spectrometry have been used
by our laboratory and others for the discovery of protein markers in complex tissues [125,
127, 139, 140] . This combination of techniques permits simultaneous examination of
hundreds of proteins from a nearly pure cell population removed from a heterogeneous
sample, however large sample requirements and the time consuming step of
microdissection, as mentioned above, will most likely prevent the implementation of this
technique beyond discovery and into the realm of clinical diagnostics. A recent
applications of MALDI MS which addresses the problems of high through-put and
sample requirements is its use to profile and image proteins directly from thin tissue
sections [141, 142]. This technique, known as MALDI imaging mass spectrometry
(MALDI IMS) was pioneered by Richard Caprioli at Vanderbilt University [143]. The
method bypasses the need for microdissection and solubilization of tissue proteins prior
to analysis. MALDI-IMS methodology employs the following scheme (reviewed in [144]
and outlined in Figure 4): A matrix solution, such as sinapinic acid (SPA), is directly
deposited onto tissue sections, and the soluble proteins are extracted from the tissue and
co-crystallize with the matrix. Protonated protein ions are formed by irradiating the
matrix with a pulsed laser directly on the tissue and are separated by m/z in a MALDITOF mass spectrometer. Protein species in the mass range of 2,000-100,000 Da are then
detected in the mass spectra. If matrix is applied uniformly across the tissue section,
desorption can be targeted to specific "points" in a grid pattern and the data rasterized.
The resulting spectra can then be used to generate two-dimensional molecular maps of
hundreds of peptides and proteins directly from the surface of a tissue section. These
molecular maps display the relative abundance and spatial distribution of the protein and
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peptide molecules.
Several recent studies underscore the potential of MALDI-IMS for clinical
histopathology applications. Protein expression profiles obtained from tissue could
discriminate lung cancer subtype [145]. Tumor histology, therapeutic response, and
patient survival were shown to correlate with the protein expression patterns obtained
from direct tissue analysis in breast tumors [146, 147]. Protein expression patterns and
images were also found to correlate with brain tumor histology and patient survival [148].
Similar discovery efforts using MALDI-IMS have yielded potential candidates in
ovarian, colon and prostate cancer [149-151].
MALDI-IMS also has utility in the examination the distribution of small molecules
and peptides in tissue sections [152, 153]. Many compounds that are biologically or
pharmacologically relevant are less than 1 kDa in size and thus fall into the broad
category of small molecules Levels of drugs such as chemotherapeutic agents or
hormonal therapies can be measured directly from a tissue biopsy to assess the level of
delivery to a particular organ site [154], opening new possibilities for the measurement of
concomitant protein changes in specific tissues after systemic drug administration. The
spatial distribution of peptides in a tissue section can also be examined via MALDI-IMS
by spotting the section with small volumes of a trypsin solution to carry out in situ
protease digestion. Sequence determination of the tryptic fragments is performed using
on-tissue MALDI MS/MS analysis directly from the individual digest spots. This
protocol enables protein identification directly from tissue while preserving the spatial
integrity of the sample. This procedure was demonstrated with the identification of
several proteins in the coronal sections of a rat brain [155].

Upregulation of proteolytic activity is a feature of malignant cells [156]. Cancer
development is essentially a tissue remodeling process in which normal tissue is
substituted with cancer tissue. A crucial role in this process is attributed to proteolytic
degradation of the extracellular matrix (ECM). Degradation of ECM proteins is initiated
by proteases, secreted by different cell types, participating in tumor cell invasion [156].
Therefore the examination of endogenous peptides in PCa tissue via MALDI-IMS may
help determine clues to tumor initiation and progression pathways. Recently MALDIIMS became available on instruments that allow the measurement of mass signals with
very high resolution and precision, namely Fourier transform mass spectrometers (FTMS) [157, 158]. The spatial distributions of biomolecules differing in mass by less than
0.1 Da can be resolved, using FTICR. This represents a mass resolution not attainable
with other MALDI-TOF platforms allowing for the analysis of small metabolites and
lipid molecules.
MALDI-MSI has extraordinary benefits as a discovery tool because one does not
need to know, in advance, the specific proteins that have changed in a comparative study.
Furthermore, the cellular origins and relative concentrations of the biomarkers across the
tissue section can be assessed. Once a marker of interest is identified, its precise location,
concentration, regulation and function may be investigated, to help understand disease
progression at the molecular level. However, critical questions remain regarding the
integration of this technique with clinical decision making. The information obtained
from MALDI-IMS should significantly augment and enhance existing clinical pathology
practices, but not replace them. Obtaining protein biomarkers which are specific for a
disease or different stages of a disease would greatly benefit the ability of physicians,
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surgeons and pathologists to accurately provide patients with a "personalized" diagnosis
and prognosis. The use of this new technology for the advancement of such endeavors
holds great promise.
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CHAPTER II
DISSERTATION RATIONALE AND SUMMARY OF AIMS

The objective of this research proposal is the application and investigation of
MALDI-IMS to clinical diagnostics in the examination of prostate cancer tissue. The goal
of this clinical/translational approach is to provide a molecular assessment of tumor
progression obtained from surgery specimens, with the potential to identify tumor
subpopulations and predict patient survival beyond the current histologically determined
cellular phenotypes.
Routine diagnostic pathology represents the gold standard and plays an integral
role in the diagnosis and prognosis of cancer. Because therapeutic decisions are based on
the presumed reliability of the pathology diagnosis, a misdiagnosis can result in
unnecessary, harmful and aggressive therapy or inadequate treatment. Unfortunately,
medical studies over the last two decades have demonstrated that this gold standard is not
consistently reliable. In fact, multiple studies in various cancers have demonstrated
discrepancy rates of up to 30% with an average of approximately 10% [159].
Traditionally, pathologists use histopathological images of biopsy samples removed from
patients, examine them under a microscope, and make judgments based on their personal
experience. While examining such tissues, a pathologist assesses the deviations in the cell
structures and/or the change in the distribution of the cells across the tissue. However,
this judgment is subjective, and leads to considerable variability [160, 161]. Furthermore,
cancer staging provides only probabilities of the course of disease for any individual
patient. There still remains a mysterious heterogeneity of outcomes for patients with
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cancers of apparently equivalent type, stage and grade. While some recurrences may be
due to an incompletely removed tumor or occult micrometastasis, in other cases the
recurrence occurs in genetically altered cells in a field surrounding the area from which
the tumor was excised [162,163]. This field of genetically altered cells is defined as a
precancerous group of epithelial cells of monoclonal origin [164].
Prostate cancer is a major health burden throughout the world being the most
common cancer among men in most developed countries. The molecular pathology of
PCa is complex, and the pathways and acquired molecular alterations which are involved
in the initiation and progression of prostate tumors are still largely unknown. It is
presently not possible to predict aggressiveness in PCa and many tumors with similar
histopathological features do not behave similarly. Clearly new molecular markers of
PCa are needed to improve and assist pathologists in cancer diagnosis/prognosis.
Malignant transformation initiates alterations in protein expression. These
alterations can be monitored at the protein level, in situ both, qualitatively and
quantitatively with a recently developed technique, known as matrix-assisted laser
desorption/ionization imaging mass spectrometry (MALDI-IMS). This technique holds
promise for the discovery of new molecular markers by examining the protein signatures
present in tissue. The central hypothesis of this dissertation is that discrete protein
mediators of tumor-host interactions in prostate tumor tissues which are involved in
PCa initiation and progression, including metastasis can be identified using
MALDI-IMS. Our central hypothesis will be tested and our overall research objective
will be achieved by pursuing the following specific aims.
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AIM 1: The application of MALDI-IMS to prostate cancer diagnosis and prognosis. The
goals of this Aim are:
A. Optimization of MALDI-IMS techniques to existing clinical pathology laboratory
practices. This includes enhancing the reproducibility of matrix deposition
techniques and new fixation methods which preserve both morphology and
proteins.
B. Identification of tumor specific protein expression patterns in prostate tissue.
Comparison of the protein expression patterns of primary PCa tumor to
surrounding normal tissue will elucidate the tumor microenvironment. The protein
patterns will be analyzed with software to create classification algorithms which
can distinguish between tumor subtypes on the basis of pathology. Images of
specific m/z signal will be constructed by plotting the relative ion intensities of a
given m/z signal over all the spots, providing a plot of the spatial distribution of
that protein within the tissue. These images will also be examined for their ability
to provide diagnostic information.
C. Identification of protein expression patterns in primary prostate tumor tissue
indicative of metastatic disease. Using a cohort of patients presenting with similar
risk factors but no extra-prostatic disease at the time of their prostatectomy,
profiles and images of PCa lesions from patients with micrometastatic disease
will be compared.

AIM 2: Sequence identification and characterization of potential biomarkers for clinical
diagnostics. This Aim entails:
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A. Using fractionation and MALDI-TOF MS/MS (LIFT) methods for protein
sequence determination, the identities of the proteins and endogenous peptides
discovered in Aim 1 will be determined. The sequence identity of the
differentially expressed proteins in normal and diseased tissue will also help
elucidate key pathways that are disregulated in PCa.
B. In-situ trypsin digestion on tissue sections will be employed for the validation
(from Aim 2 A) and identification of proteins and peptides present in both PCa
and benign adjacent tissue. MALDI-TOF MS/MS will be used for sequence
identification.
C. Validation of the identities of biomarkers discovered will be determined
orthogonally with Western blot analysis and immunohistochemistry
D. Characterization of biomarkers identified and their role in cancer initiation and/or
progression by the examination of related molecules. This will be performed
using imunohistochemistry and/or Western blot techniques.

AIM 3: Evaluation of the clinical utility of MALDI-IMS biomarkers. The goals of this
Aim are:
A. Using a cohort of surgery specimens the clinical utility of biomarkers and protein
expression patterns found and identified in Aims 1 and 2 will be evaluated. Tissue
samples will be blinded and the diagnosis based on MALDI IMS imaging and
spectral analysis will be compared with diagnosis made by clinical laboratory
pathologists.

CHAPTER III
AIM 1: THE APPLICATION OF MALDI-IMS TO PROSTATE CANCER
DIAGNOSIS AND PROGNOSIS

3.1 Introduction
Prostate cancer is the most common cancer, other than skin cancers, in American
men. The American Cancer Society estimates that during 2008 about 186,320 new cases
of prostate cancer will be diagnosed in the United States [30]. In addition, prostate
cancer is the only tumor for which diagnosis is exclusively based on biopsies, placing a
large burden on the ability of pathologists to both detect and predict the course of the
disease. Current markers poorly predict early disease development and tumor
aggressiveness [71]. If you add the fact that PCa is usually heterogeneous and multifocal,
with diverse clinical and morphologic manifestations, it is clear that here is a desperate
need for molecular markers to aid pathologists. Currently, surprisingly little is known
about early molecular alterations in prostate cancer, but several studies have found that
considerable molecular changes precede morphologically detectable malignant
transformation of prostate epithelial tissues [165]. The correlation of molecular
information to histopathological structures offers tremendous potential for improved
characterization of PCa leading to novel strategies in the clinical management of prostate
cancer.
Cancer biomarker discovery has been and continues to be an active and
productive area of research and scientists are using ever more sophisticated and
innovative technologies in this effort. Unlike traditional biomarker approaches to obtain
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proteomic information, mass spectrometry provides for an extremely rapid and
potentially high-throughput platform for biomarker discovery. This powerful technology
can identify all proteins and their posttranslational modifications in disease conditions,
and hence will greatly accelerate progress toward novel diagnostic and prognostic tools to
track early disease. The use of MALDI-IMS and profiling to obtain such molecular
information in the form of protein and peptide distributions greatly enhances the ability to
identify potential candidates for new specific biomarkers. In their groundbreaking study,
Caprioli and Carbone showed that proteomic patterns obtained directly from small
amounts of fresh frozen lung-tumor tissue could be used to accurately classify and predict
histological groups as well as nodal involvement and survival in resected non-small-cell
lung cancer [145]. Similar results were obtained for ovarian cancer in which peptide
profiling by direct MALDI analysis of 25 ovarian carcinomas (stages III and IV) and 23
benign tissues identified several peptides observed to be present only in carcinoma
compared to benign samples [166]. The most prevalent peptide was identified as a
fragment of immunoproteasome PA28. Specific to prostate tissue, MALDI-IMS revealed
a specific expression pattern that was temporally associated with prostate development in
an animal model [167] and in a separate study a protein expression pattern was associated
with pathogenesis of prostate cancer in a cohort of 22 prostate tissue samples [150].
A major advantage of MALDI-IMS is the avoidance of time-consuming
extraction, purification or separation steps, which have the potential for producing
artifacts [104]. The reliable and sensitive detection of changes to the proteome in tissue
samples is an important challenge and will require standardization and optimization of
methodologies. The second most important challenge is the integration of MALDI-IMS
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into existing clinical pathology laboratory practices. All of the protocols developed to
date for protein analysis by MALDI-IMS have been optimized for freshly frozen tissue
specimens. Snap-freezing of tissue samples is ideal from a protein stand point, because
no processing is involved and, when performed rapidly, avoids protein degradation
through proteolysis. However, frozen tissue is often difficult to process and store for most
pathology labs. Historically, tissue samples analyzed in pathology laboratories undergo
formalin fixation, dehydration through graded alcohol series, and paraffin embedding.
Although the morphology of formalin fixed tissues is superior with respect to fresh
frozen samples, the molecular cross-linking by formalin renders proteomic analysis
almost impossible [168].
A recently introduced histologic fixative (Universal Molecular Fixative, UMFix)
has been shown to preserve macromolecules (DNA, RNA and proteins) in tissue at
ambient temperature [169,170]. A recent study found that the intensity of
immunohistochemical reactions for most cytoplasmic antigens was generally equal or
stronger in UMFix treated tissues when compared to formalin fixed tissues [171].
Therefore UMFix would seem an ideal choice for the processing of clinical pathology
specimens for MALDI-MSI, but protocols for sample preparation, storage and data
collection need to be optimized and evaluated. Another important aspect of sample
preparation is the homogeneous deposition of the MALDI matrix on the tissue sample in
such a way as to avoid significant lateral migration of proteins on the surface of the
section. The matrix can either be deposited as individual spots or spray coated as a
homogeneous layer. Evaluation and optimization of matrix deposition is crucial to
provide consistent results in diagnostic clinical applications.
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In Aim I we refine and optimize sample preparation and MALDI-IMS protocols
for specific molecular imaging of prostate tissue with emphasis placed on compatibility
with current clinical pathology methodologies, by using fixed tissue. An initial cohort of
PCa and normal tissues was used to standardize existing protocols. We compared protein
profiles of bulk tumor to surrounding normal tissue and profile the tumor
microenvironment to probe tumor-host interactions in this initial data set. Additionally,
we contrast protein profiles of metastatic lesions with surrounding normal tissue and in
tissue obtained from matched patients with similar risk factors who did not develop extraprostatic disease. The imaging and protein profiling of these tissues has provided us with
a critical evaluation as to the utility of the method and capacity to resolve the protein
signals from different cell types in close proximity. The comparison of the protein
profiles and images generated using MALDI-IMS in a large cohort of prostate cells with
different pathological sub-types enabled us to detect PCa in tissue samples.

3.2 Materials and Methods
Materials
Acetonitrile, ethanol, high-performance liquid chromatography (HPLC) grade
water, 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid-SPA) were purchased from
Sigma Chemical Co. (St. Louis, MO). (HCCA) a-cyano-4-hydroxycinnamic acid was
purchased from Bruker Daltonic. Tri-fluoroacetic acid (TFA) was purchased from Pierce
Biotechnology, (Rockfold, IL). UMFix (Sakura Finetek USA, Inc.) is a mixture of
methanol and polyethylene glycol at a predetermined ratio as previously described (US
patent application number 10/141, 780).

Patients and Tissue Samples
Patients were consented prior to undergoing radical prostatectomy at Sentara
Norfolk General Hospital. Study protocols were approved by the institutional review
board at EVMS. The age range of the patients was 46-69 with a mean age of 57 years
who underwent surgery between 2003 and 2008. A total of 59 patients were recruited for
this study. Two cored specimens were harvested from each prostate immediately after
removal of the organ. One core was fixed in formalin or UMFix and paraffin embedded
and the other was embedded in OCT (optimal cutting temperature compound, Sakura
Finetek USA) and frozen at 80°C. A total of 72 frozen tissue blocks were acquired from
prostatectomy tissue. The frozen blocks yielded 36 sections of benign tissue (distal from
tumor site), 36 sections of PCa containing tissue (Gleason grades 6-10) with 25 harboring
benign adjacent tissue. Additionally, 12 tissues collected from patients who developed
metastatic disease after their surgery and 7 matched tissues from patients presenting with
similar risk factors but no metastatic disease were harvested for this study. Cryosectioning was performed on a Microm HM 505E cryostat at -20°C. A serial cryosection
at 8 urn was stained with hematoxylin and eosin [172] as a guide, and analyzed by a
pathologist to determine tissue morphology. Two additional serial sections at lOum were
mounted on conductive Indium-Tin Oxide (ITO) coated glass slides (Bruker Daltonic,
Billerica, MA) and used for MALDI-IMS.

Processing and Sectioning of Fixed Tissue
Formalin fixed surgery specimens fixed in 10% neutral buffered formalin and
processed overnight in a standard processing machine [173]. Mirrored tissue blocks from
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the same surgery specimen were fixed in the UMFix and processed according to a
recently processed in a V.I.P. tissue processor (Sakura Finetek, Inc., Torrance, CA) as
recommended [174]. Sectioning was performed on a Reichert-Jung microtome model
2030. Initial sections were cut (8um) and stained with hemotoxylin and eosin for
histopathological evaluation by a pathologist. Serial sections were then made (lOum) and
placed on ITO coated slides for MALDI-IMS. The slides were then de-paraffinized by
heating to 45 °C and for 3 minutes followed by xylene treatment for 1 min. The sections
were incubated in 100% followed by 95% ethanol for one minute each and then air dried.
Slides were stored in a dessicator until spray coated with matrix.

Tissue Section Preparation
Immediately after sectioning, the ITO coated slides containing OCT embedded
frozen tissue sections were washed and fixed with 70% ethanol and 95% ethanol for 30s
each. A water wash was performed to remove residual embedding media followed by a
repeat of the ethanol washes of 70% and 95%. Slides were air dried and stored in a
dessicator for 1 hour before matrix deposition. A matrix solution of sinapinic acid (10
mg/ml) containing 75% acetonitrile and 0.13% TFA was sprayed uniformly over the
tissue using an automated spraying device, (ImagePrep Bruker Daltonics) which controls
matrix deposition and thickness of the matrix layer. Digital images of the sprayed tissue
sections were acquired with a flatbed scanner prior to MALDI analysis.
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MALDI-IMS Analysis and Image Processing
Spectra were collected across the entire tissue area using the Ultraflex III
MALDI-TOF/TOF instrument (Bruker Daltonics) with a SmartBeam laser operating at
200 Hz in linear mode over a mass range of 2,000 to 45,000 Daltons. A laser spot
diameter of 50 urn and a raster width of 100 um were employed. Using the Flexlmaging
software (Bruker Daltonic), teaching points were generated to ensure the correct
positioning of the laser for spectral acquisition. The software exports the specific
geometry of the tissue to be analyzed and an instrument specific automated method is
created which generates a grid across the tissue of spots where the laser will acquire data.
A total of 200 laser shots were accumulated and averaged from each laser spot rastered
across the tissue section. Calibration was performed externally using a peptide standard
in the mass range of 700-4500 Da. The intensity of each signal over the entire mass range
acquired is plotted as a function of location on the tissue allowing the visualization of the
location of each m/z detected. These images were generated and visualized using Flex
Imaging and Biomap software (available as free software from www. MALDI-MSI.org.).

Data Processing and Statistical Analysis
Automated analysis of the spectral data was performed to identify all
differentially expressed peaks between cell types. Spectra derived from defined Regions
of Interest (ROI) in each tissue were exported using the Flexlmaging software for profile
analysis. Base-line subtraction, normalization (to total ion current), peak detection, and
spectral alignment were performed using ClinProt. A mass window of 0.3% and a signal
to noise ratio of 3 were selected for peak detection. A genetic algorithm (GA) using k-
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nearest neighbors (KNN) was used to obtain a classification between normal and PCa
containing tissue. The result of the GA is the peak combination which is proved to
separate best between the different classes. Significant differences between groups were
determined by Student's t test. A P-value of less than 0.01 was considered to indicate
statistical significance. The predictive power of the putative biomarker to detect PCa
tissue areas was tested using the area under the receiver operator characteristic (ROC)
curve using SPSS for Windows. The optimal cut-off point was defined as that point on
the ROC curve that maximizes both sensitivity and specificity.

3.3 Results
Optimization of Matrix Deposition
Recently our laboratory acquired a new device for the spray coating of tissue
sections for with matrix for MALDI-IMS. In this device (ImagePrep, Bruker Daltonics),
a matrix aerosol is created by vibrational vaporization under controlled conditions. An
average droplet size of-20 um is generated and all droplet diameters are < 50 um. For
quality control an optical sensor monitors the light scattered from matrix crystals to
control the preparation parameters in real-time. These parameters include: deposition
periods and intervals, matrix layer thickness, wetness, and drying rate. During the wetting
period the scattered light intensity fades while drying increases the intensity due to
crystal formation. At complete dryness the signal received by the optical sensor is a direct
measure of the thickness of the matrix layer. We evaluated the reproducibility of this
instrument using serial sections from the same tissue specimen. As shown in Figure 5, the
uniformity of the spray coating is consistent across each sample and duplicate samples
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Figure 5. Comparison of hand spraying with a TLC sprayer to automated spraying using
the ImagePrep device. A.) Two representative slides hand sprayed with SPA matrix (20
passes). B.) Three sets of two serial tissue sections sprayed with the ImagePrep
automated spraying device. Also shown are the accompanying MALDI-IMS images of a
common m/z value of 11303.5 showing reproducibility of the images produced.
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and far superior to hand spraying (a method we evaluated initially using a TLC sprayer).
This reproducibility in matrix coating resulted in reproducibility of spectrum and images
produced across duplicate tissue sections.

Identification of an Expression Profile that Discriminates between PCa and
Adjacent Normal Tissue
Our investigation into the presence of a PCa specific protein/peptide expression
profile was conducted on a total of 72 frozen prostate tissue samples derived from 59
patients. The patient and tissue sample characteristics of this cohort are presented in
Table 1. Tissue sections were uniformly coated with matrix using the automated spraying
device, and adjacent serial sections were stained with hemotoxylin and eosin (H&E) for
histopathology. Parallel stained slides of each section were read by a genitourinarytrained pathologist and the regions of interest (ROI) designated. These ROI contained
prostate adenocarcinoma cell populations, benign adjacent epithelial cells, as well as
stroma and benign epithelial cells from tissue specimens without tumor cells present. In
an initial survey experiment we analyzed 22 tissue sections (11 PCa and 11 benign). The
resulting spectra were used to generate two-dimensional molecular maps of the peptides
and proteins present in each tissue section and automated analysis of the spectral data was
performed to identify differentially expressed peaks. Several peptide ions were found to
discriminate PCa from benign tissue (Table 2). Examination by a pathologist reveals
specific regions with designated cell types present in prostate tissue sections (Figure 6A).
In the mass range m/z 3000-5000 several differentially expressed ions were detected
which could be used to discriminate between PCa and adjacent benign regions (Figure 6B
inset and Table 2). Of particular note are two peptide ions with an average m/z of 4027,
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Table 1. Patient and Tissue Sample Characteristics
Characteristics
Mean age years (range)
Mean preoperative PSA ng/ml (range)
Tumor volume (%)

N
57 (46-69)
10.2 (3.6-37.5)
21.3

Pathological classification
pT2a
pT2b

8

PT2c

23

PT3a

20

PT3b

5

3

Total Patients

59

PCa containing tissue
Gleason Score

36

4-6
7
8-10

20
16
0

Adenosis

2

Benign

36

Total Tissue Samples

74

Table 2. Peaks Used to Discriminate PCa from Benign Adjacent Tissue
Peaks highlv expressed in PCa cells (m/z)
3373
3443
3487
4027
4355
Peaks highlv expressed in benign adjacent cells (m/z)
4274
% Cancer correctly classified
% Benign areas correct

81.7
59.8
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Figure 6. Direct tissue mass spectrometric analysis of human prostate tissue reveals cellspecific profiles. Frozen prostate tissue was processed for MALDI imaging and coated
with SPA matrix followed by spectra acquisition in linear mode. A) Representative
histology image of H & E stained prostate tissue showing areas of prostate
adenocarcinoma (T) benign prostate glands (B) and benign stroma (S). B) Resulting
spectra acquired from each region indicated showing characteristic profiles for different
cell types. Bottom panel inset) Expanded view of the mass range m/z 3000-5300 showing
differences in the profiles for each cell type
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and 4355 which showed significant over-expression in PCa cells when compared to
benign adjacent cells spectra. Three ions over expressed in PCa (3,372, 3,443, and 3,487)
are consistent in mass with defensin peptides and may be indicative of infiltrating
neutrophils [175, 176]. Another peak at m/z All A was expressed in benign adjacent
epithelial cells and stroma with little or no expression seen in PCa cells. Spectra derived
from ROIs designated tumor or benign from the initial 22 tissues examined were used to
generate a classification algorithm capable of correctly classifying 85% of PCa tissue
areas and 50.2% of benign regions. Selected component ions with significant
discriminating power were evaluated in these initial tissues and images derived around
the pathology-designated ROI. This allowed for a visual determination of region specific
changes in peptide ion expression. Representative examples of images derived from three
regionally discriminating ions are shown in Figure 7. An additional classification
algorithm using 5 differentially expressed m/z values (3443, 3442, 4030, 4275. 4355) was
also developed. This algorithm was able to correctly classify 90.3% of the PCa
containing regions, but only 64.1% of the benign regions were correctly classified (Table
3).

MALDI-IMS Utilizing m/z 4355 Can Identify PCa Specific Regions of Prostate.
When we examined the list of differentially expressed peaks from our initial set of
22 tissues, the ion at m/z 4355 was the most significantly over-expressed ion, in PCa
containing tissue regions (p = 2.76 x 10" ). We therefore wanted to further evaluate the
utility of this peak alone for the detection of PCa regions within prostate tissue via
MALDI-IMS. Figure 8 is a representative image of a tissue section with one specific
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Figure 7. MALDI-IMS utilizing specific m/z values can identify PCa specific regions
within the prostate. Direct profiling of human prostate tissues revealed specific peaks
both over and under-expressed in PCa regions. A) Composite spectra showing
characteristic profile for PCa regions (top line) and benign adjacent regions (bottom line)
indicating the overexpression of 2 peaks at m/z 4355 and m/z 4027 and underexpression
of m/z All A. B) Left- H & E stained histological image of a representative tissue
containing an area of PCa circled by a pathologist with a 10X view of the cancerous
glands (inset). Right- Corresponding images indicating the expression pattern for each
peak shown in a) and the combined image for all three peaks.
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Table 3. Genetic Algorithm for PCa vs. Benign Tissue Classification

Peaks used in classifier (m/z)
3443
3488
4027
4275
4355
Correct classification
PCa areas:

90.3 %

Benign Areas

64.1 %
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region of PCa cells and clearly defined adjacent regions of normal prostate glands. A
higher magnification view of each cell type can be seen in the insets. Clearly evident
from the ion density map, the m/z 4355 peak was highly expressed in the PCa region as
compared to the surrounding tissue. Little to no expression is visible in the normal stroma
or benign glandular regions. When representative spectra were exported from the specific
regions (tumor vs. benign) we can clearly observe a prominent peak at m/z 4355 overexpressed in the PCa obtained profile.

MALDI-IMS Utilizing m/z 4355 Discriminates between Cancer and Uninvolved
Prostate Tissue.
In order to evaluate the differential expression of m/z 4355 between PCa and
benign regions we conducted an analysis of the full set of prostate tissue derived from
radical prostatectomy. We examined the images produced from the ion density of the m/z
4355 peak following the analysis of 36 PCa and 61 benign tissue sections. The benign
tissues were both distal (n=36) and adjacent (n=25) to tumor. Shown in Figure 9 are
representative ion images of the expression of the m/z 4355 peak in 4 tissue sections
containing PCa (Figure 9 A.-D.) and 4 distal benign sections (Figure 9 e.-FL). The
corresponding spectra in the representative region of m/z 4000-4600 are shown in the top
panels above each image. High expression (defined as > 2x the normalized peak intensity
of the benign regions) was visible in each section where PCa cells were present (Figure 9
A. and D.) or visible throughout the tissue when no benign cells were present (Figure. 9
B. and C). In contrast, little to no expression of the m/z 4355 ion was detected in sections
containing benign cells only (Figure 9 E.-H.). In order to illustrate the tissue specific
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Mass to charge (m/z)

Figure 8. MALDI-IMS utilizing m/z 4355 can identify PCa specific regions of prostate.
A) H & E image of a tissue specimen containing a defined area of PCa glands and benign
glands. Magnified (lOx) views of each cell type are shown in the insets. B) Resulting 2D
ion density map of the tissue showing high expression of a peak at m/z 4355 (bottom
circle) in the PCa area (inset is a scan of the tissue after matrix deposition). C)
Representative spectra obtained in the PCa region from the benign adjacent glandular
area displaying differential expression of the ion at m/z 4355
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Figure 9. MALDI 2D ion density maps of 4 PCa containing tissues and 4 benign prostate tissue specimens.
Tissues obtained from 8 patients undergoing radical prostatectomy were processed for MALDI imaging and
2D ion density maps were generated (middle panels) showing expression of the peak at m/z 4355. A-D) Tissue
specimens with defined regions of PCa (circled) or throughout the specimen visible from H & E serial sections
(bottom panels). Areas in red (bright areas) from the resulting MALDI-IMS indicate high expression of m/z
4355. E-H Benign prostate tissue showing little to no expression of the m/z 4355 peak. Spectra exported from
representative regions of each tissue are shown in the m/z range of 4000-4600 and display the m/z 4355 peak
profile (top panel). Intensity scale for the images is shown bottom right.
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expression of m/z 4355, we examined the intensity values with respect to defined tissue
regions across the full data set. Intensity values normalized to total ion current for the m/z
4355 peak were calculated for each tissue region (PCa, benign adjacent, and benign
distal) and plotted (Figure 10). The average intensity of the m/z 4355 peak in benign
adjacent or distal tissue was 30.2 and 27.6 respectively, whereas for PCa regions the
average intensity was 71.8, representing a 2.5 fold increase. A total of 75% (n=26) of the
PCa regions exhibited average intensity values for the m/z 4355 peak above the average
intensity for benign regions. A ROC curve calculated from the average normalized
intensity of each ROI (distal benign vs. PCa) is shown in Figure 11. The optimal cutoff
point for using the m/z 4355 peak as a biomarker for PCa in tissue sections was a
normalized average intensity value of 27. This cutoff point was associated with a
sensitivity of 75.0% and a specificity of 74.3% (AUC 0.834). Of the 25% (n=9) of PCa
samples with values at or below the cut-off, two were from tissues containing
pseudohyperplastic PCa (characterized by the presence of larger glands with branching
and papillary infolding), and one was a specimen with cribriform PCa (relatively large
epithelial cell masses perforated by multiple small lumens, Gleason grade 4+3).
Interestingly one specimen below the cut-off was from a patient treated with hormone
ablation therapy prior to surgery, also a Gleason grade 4+3 (no other patients in the study
received pretreatment). Of the remaining 5 tissues with low expression of the ion at m/z
4355, three were Gleason grade 3+4, and two were Gleason grade 3+3. No other
remarkable morphological differences were seen for these tissue sections.
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Figure 10. Normalized average intensity values for m/z 4355 in different prostate tissue
areas. A total of 36 PCa containing tissues 25 benign adjacent and 36 distal benign tissues
were analyzed via MALDI-IMS. The resulting normalized average intensity values for
the m/z 4355 peak were plotted for PCa, benign adjacent and benign distal regions. The
boundary of the box closest to zero indicates the 25th percentile, a line within the box
marks the median, and the boundary of the box farthest from zero indicates the 75th
percentile. Whiskers above and below the box indicate the 90th and 10th percentiles. *
Significant p value.
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Figure 11. ROC curve for m/z 4355. The predictive power of the putative biomarker to
detect PCa tissue areas was tested using the area under the receiver operator characteristic
(ROC) curve. The area under the curve (AUC) = 0.834.
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Specific Morphological Features are Associated with the Expression of m/z 4355 in
PCa and atrophic Prostate Glands
The careful examination of areas expressing the ion at m/z 4355 revealed that
certain specific morphological features in prostate tissues are associated with this
expression. As shown in Figure 12, two representative PCa areas from moderately
differentiated tumors exhibiting distinct m/z 4355 expression have infiltrating
lymphocytes surrounding the cancerous glands (small arrows). Infiltrating lymphocytes
were also observed in one case of proliferative inflammatory atrophy (Figure 13 A) and
another case of benign tissue where cystic atrophy (Figure 13 B) was present, both in areas
expressing the m/z 4355 ion.

Identification of an Expression Profile using MALDI-IMS for the Detection of
Metastatic Disease
Frozen prostate sections of similar stage disease in which the case/control design
is the discovery of metastatic disease after surgery in the case group were analyzed for
protein expression differences using MALDI-IMS. We concentrated on differential
expression patterns of the tumor tissue regions between case and control. We have
examined 12 PCa tissue samples harvested from patients with micro-metastatic disease
and 7 tissues from patients with PCa and similar risk factors (PSA level, Gleason score)
but no metastatic disease. From this dataset we have generated a list of top discriminating
spectral peaks that are presented in Table 4. We then plotted several of the m/z for image
generation and subsequently compared the images to the mirrored histologically stained
and pathology read sections. In Figure 14 representative images from MALDI-IMS show
two peaks (4030 and 5364) found to be highly expressed in case samples when compared
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Figure 12. Specific morphological features are associated with the expression of the ion
at m/z 4355 in PCa tissue. Two tissues with moderately differentiated PCa regions circled
in the H&E stained section (top left A and B). High expression of m/z 4355 (circled) as
viewed in images produced via MALDI-IMS (top right in each panel) corresponds to
regions of PCa with accompanying lymphocytic infiltrates. Bottom images are 1 OX,
views of specific regions from the serial H&E stained section with 20X views of areas
containing infiltrating lymphocytes (small arrows).
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Figure 13. Specific morphological features are associated with the expression of the ion
at m/z 4355 in non-neoplastic lesions. Two tissues with PIA (A) and atrophic regions (B)
circled in the H&E stained section. High expression (circled) of m/z 4355 (top right in
each panel) corresponds to regions of atrophy inflammation with accompanying
lymphocytic infiltrates. Bottom images are 10X views of specific regions of infiltrating
lymphocytes (small arrows).

Table 4. Differentially Expressed Peaks in PCa Tissues from Patients
with Micro-metastasis

m/z
4030
5364
9533
6186
3230

normalized intensity
Match
Target
61.41
61.72
21.32

41.18
42.96
8.4

p-value
2.59E-88
3.97E-83
1.13E-79
8.75E-64

45.48
65.12

6.79E-56

3817

83.43
31.93
35.17

59.12

1.57E-52

3245
9767

24.86
25.07

36.88

1.17E-51
3.56E-47

8963

42.24

9091
9021

50.71

10.78
14.39

17.39
37.64

6.28
31.13

6344

8.85

3.59E-46
8.89E-45
1.39E-42
5.49E-39
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Figure 14. MALDI-IMS analysis of PCa containing tissue obtained from micrometastatic
patients (target-case) and patients with matching risk factors at the time of surgery
(match-control). The expression patterns of two m/z values found over-expressed in the
target tissues are shown. A) Left-Target tissues showing high expression of m/z 4030
(top) and m/z 5364 (bottom). Right- Matched tissues showing reduced expression of m/z
4030 in all three matched tissues (top), and reduced expression in 2 of 3 for m/z 5365
(bottom). B.) H & E of two tissues represented in A.) showing circled areas of PCa with
similar morphology and the same Gleason grade of 3+4.
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to control specimens. Additionally, the m/z 4355 peak was not found to be discriminatory
for these samples as expected since PCa was present in both groups. A 2D peak
distribution view for the two most discriminatory peaks (m/z 4030 and m/z 5365) is
shown in Figure 15. The samples from patients with metastatic disease are separated from
the matched controls with some overlap in both groups. We next developed a
classification algorithm using 6 differentially expressed peaks (m/z 331 A, 3751, 3817,
4030, 5364, and 5664). As shown in Table 5, this algorithm was able to correctly classify
the PCa tissues from patients who harbored micrometastatic disease at a rate of 83%.
However, the algorithm's ability to correctly classify tissue samples from patients
without extra-prostatic spread was only 58%.

MALDI-IMS of fixed tissue
Fixed tissue provides the best histological morphology, but classical methods
such as formalin fixation cross-link proteins and are therefore not useful for proteomic
analysis. In order to facilitate the use of MALDI-IMS into current clinical laboratory
methods we wanted to determine if the "protein friendly" fixative (UMFix) was
compatible with MALDI imaging. To assess the quality of the spectrometric data and to
better understand the effect of the fixation procedure, profiles and images obtained from
the UMFix processed samples were compared to those obtained from OCT embedded
frozen samples. For the UMFix specimens, after sectioning, paraffin removal and partial
rehydration (protocol shown in Figure 16), MALDI matrix, (SPA) was sprayed on the
tissue following our established protocol using the ImagePrep workstation. We evaluated
prostate tissue treated with UMFix to obtain spectra and images via MALDI-IMS. The

67

Table 5. Genetic Algorithm for Detection of Micrometastatic Disease
Peaks used in classifier (m/z)
3374
3751
3817
4030
5364
5663
Correct classification
Case:

82.8%

Control

58.2 %
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m/z 5364

m/z4030
Figure 15. 2D peak distribution plot of PCa tissue from patients harboring micrometastatic disease. Individual peak values for Target (case) versus (matched controls) are
displayed for the two most discriminatory peaks (m/z 5364 and m/z 4030).
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Tissue is fixed in UMFix for Ihour
and embedded in paraffin

Tissue is sectioned at IGum
and placed on a conductive slides

Slides are placed at 45^ C for 3 minutes
then xylene for 1 minute to get rid of paraffin

*

Tissue is washed in 70% EtOH, 95% EtOH
and coated with matrix

Figure 16. Flowchart of processing protocol for UMFix treated tissue before MALDIIMS.
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matched mirrored frozen and formalin fixed tissue was also processed for comparison.
Representative spectra resulting from this comparison are shown in Figure 17. As
expected, the formalin fixed tissue did not produce any protein peaks. The UMFix treated
tissue however produced spectra with signal intensity and peak pattern similar to that
obtained from OCT embedded frozen tissue. The minor variations in peak intensities may
be due to variations in areas sampled or an unknown modification of proteins during the
fixation process. This phenomenon will need to be evaluated and characterized in further
studies.
We also examined resulting images from two sets of matched fixed and frozen
tissue produced after conversion of the spectra to a 2D ion map using BioMap. As shown
in Figure 18, the area of overexpression of the m/z 4355 peak in the resulting images
corresponds well in both the UMFix and frozen tissue. The areas showing high
expression of m/z 4355 were designated by a pathologist to be proliferative inflammatory
atrophy (PIA) and cystic atrophy. PIA is believed to be a precursor lesion to PCa. These
results indicate that the UMFix processed tissue is compatible with the MALDI-IMS and
preserves detail in the subsequent images, producing comparable results to frozen tissue.

3.4 Discussion
In a previous study we established that SELDI-MS (a variant of MALDI) protein
profiles from lysed prostate cells (isolated via LCM) obtained from different disease
states had discriminating peak differences [127]. The results of our current study
demonstrate that both the protein profiles as well as the resulting molecular image maps
are discriminatory. In this study we employed MALDI-IMS in an attempt to discriminate
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Figure 17. Comparison of MALDI-IMS spectra derived from prostate tissue samples
which were fixed (UMFix or formalin) or frozen.
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tumor from benign adjacent prostate tissues. After an initial discovery via profiling in a
subset of (11 PCa/11 benign), we tested the performance of selected biomarkers across a
large tissue set of 36 PCa and 61 benign tissue sections. The performance of a single
biomarker (m/z 4355) was associated with the corresponding image for the detection of
PCa. Thus, the expression changes detected in tissues by MALDI-IMS may reflect
molecular pathway changes indicative of PCa development. We also show that the
commercial fixative, UMFix, preserves expression detail similar to that found in frozen
tissue, at least for some markers.
Any new technology will only be useful to patient care if it is adopted by
clinicians. In order for MALDI-MSI to be clinically useful it must contribute to the
ability of pathologists and surgeons to make accurate diagnosis and prognosis. Since
pathologists are familiar with the use of images to make diagnosis, the use of molecular
images should translate more readily to this end. This study was undertaken to assess the
feasibility of the use of MALDI-IMS for the elucidation of peptide and protein
expression differences prostate tissue sections as well as determining the clinical
feasibility of this technique to produce images which correlate with histopathology. In
addition we have identified a potential marker for prostate cancer which may aid in the
detection of prostate cells in a surgery specimen.
A weakness of our study is the lack of high grade PCa tissue to examine the
expression of the m/z 4355 peak. There is some indication from our data that the ion at
m/z 4355 is reduced in high grade PCa and increased in well differentiated tumors as well
as PIA lesions (a putative PCa precursor). Three PCa tissues with a Gleason score of 9 or
higher had normalized intensity values below the cut-off value of 27. Unfortunately, we
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did not have enough high grade tissue samples to make an accurate estimation of this
decrease. Therefore this marker may be a true biomarker of early disease and the tissue
changes associated with cancer initiation. Morphological features associated with the
expression of the ion at m/z 4355 include infiltrating lymphocytes. Moreover the
expression of defensin peptides in the spectra derived from PCa areas indicates the
presence of neutrophils. Inflammation involves the induction of complex coordinated
chemical signals and physiological processes following injury to promote "healing" of
damaged tissues. Early responses include increases in vascular permeability and
activation, together with the directed migration of leukocytes (neutrophils, monocytes
and eosinophils) towards the site of injury for the formation of a new ECM. Our results
point to an association of inflammation in the areas with higher expression of the m/z
4355 peak both in PCa and atrophic lesions.
Further studies using additional tissue including high Gleason grade tissue are
needed to validate and assess the utility of this marker. However, its true usefulness lies
in its ability to detect cancer cells in a minute amount of tissue such as in biopsy samples
which we are currently undertaking. Sequence identification and enhanced functional
analyses of the m/z 4355 peaks and other differentially expressed protein markers will not
only advance our understanding of the patho-mechanisms and aid in elucidating potential
drug targets, but may also serve as diagnostic and prognostic tools for better patient care.
Although clinically localized prostate cancer can be treated with androgen
ablation, surgical resection or radiation, its transition to metastatic disease is almost
uniformly fatal. The molecular differences between metastatic prostate cancer and
localized prostate cancer have not been well established. Before rational therapies can be
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developed to target this lethal form of prostate cancer, the molecular alterations
associated with the transition of indolent to an aggressive PCa phenotype need to be
revealed. From our MALDI-IMS analysis, we have identified several m/z values which
are differentially expressed in tissues derived from patients harboring metastatic disease
at the time of surgery to remove their prostate. The sequence identification of these peaks
should elucidate the molecular hallmarks associated with aggressive characteristics. As
no test performs perfectly, sensitivity, specificity and cost become trade-offs in the
application of diagnostics to disease management. The classification algorithm developed
was helpful, in that it correctly identified 83% of tissue samples from micrometastatic
patients. Unfortunately in 42% of the control PCa tissues, our algorithm was incorrect in
classifying PCa from patients with organ confined disease. The combination of this
algorithm with other screening methods may potentially increase its usefulness and a
trade-off of sensitivity to specificity could benefit patients at risk for the development of
metastatic PCa. Preoperative identification of patients with metastatic disease would be
helpful in sparing men from the morbidity of a radical prostatectomy that would be
ineffective or for selecting patients best suited for clinical trials of new therapies.
Clearly for this and other tissue-based markers the greatest utility will be realized
in the actual biopsy sample. To that end, our study investigating the commercially
available UMFix approach developed at the University of Miami (33) is critically
important. We have demonstrated that UMFix processed tissue is highly compatible with
MALDI-IMS methods and the resulting data and images closely correlate with those
collected from traditional methods employing frozen tissue. This makes the transition for
this new technology into current clinical pathology practice much more feasible and will
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facilitate its incorporation at a much improved pace. Future studies will need to parallel
extensive analysis of the quality retained for clinical analysis via morphology and
immunostaining. Ultimately, such changes in the tissue fixation routinely conducted by
pathology will require either a commitment to move away from highly toxic formalinbased approaches toward less toxic alcohol preparations and/or the discovery of a
biomarker specific to non-formalin tissues that revolutionizes clinical diagnostics.
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CHAPTER IV
AIM 2: SEQUENCE IDENTIFICATION AND CHARACTERIZATION OF
POTENTIAL BIOMARKERS FOR CLINICAL DIAGNOSTICS

4.1 Introduction
MALDI-IMS experiments logically lead to the sequence identification of the low
molecular weight protein species that show tissue location-specific or disease-related
changes. This has been one of the more difficult hurdles to overcome for MALDI-IMS
and remains one of the most challenging aspects to protein biomarker discovery in
general. Once a biomarker is conclusively identified, a more sensitive immunological or
enzyme-based assay may then be developed to accurately determine and measure the
molecule of interest in normal and disease samples [25, 177, 178]. Thus, deciphering the
chemical identity of protein biomarkers may facilitate more robust and sensitive tests to
detect, monitor and possibly target these new protein biomarkers in cancer.
As the molecular weight of a compound increases, its physical properties places
limits on the utility of a mass spectrometer to detect it with high resolution [179]. As
mass increases, the natural isotopic envelope distributes the population of molecules
across multiple species, resulting in broader peaks. This is not a result of an instrumental
limitation but is a fundamental property of biomolecules and is therefore insurmountable.
Additionally, high molecular weight molecules require a larger amount of energy to
ionize than low molecular weight species and therefore the ability to detect these
molecules is decreased. Because of the inefficiency of MALDI -TOF mass spectrometers
to resolve [101] and detect higher molecular weight compounds [180] most signals
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detected are below m/z 30,000. However, the localization of larger proteins may be
facilitated by the use of in situ digestion of the proteins in a tissue section. The smaller
peptide fragments generated by such enzymatic cleavage are much easier to detect by
MALDI-IMS, and should still represent the abundance of the parent protein.
Furthermore, the spatial positions of the parent protein can be inferred from the
localization of the fragment [149,155] in reflectron mode. MALDI-TOF instruments
with reflector technology offer the possibility to measure in linear mode as well as in
reflectron mode. In reflectron mode, all incoming ions are reaccelerated after deceleration
to achieve an increase in resolution making peptide analysis possible. The resulting
peptides can be visualized to provide spectra for profiling, but they can also be directly
sequence identified via MALDI-TOF tandem MS.
The analysis of mass spectra and identification of proteins is usually performed by
searching within protein or DNA databases using different search algorithms. Therefore,
complete protein or genome databases are required as only proteins of organisms with
already sequenced genomes can be analyzed this way. The fragments generated from a
tandem MS analysis provide amino acid sequence information to identify the peptide. In
the majority of mass spectrometers, this can only be performed in a limited mass range
(usually 600-4500 Da) [108]. Unfortunately, many low abundant markers fall below the
level of sensitivity currently available in MALDI-TOF MS/MS instruments for direct
tissue analysis. If this is the case, the only hope currently for identification is to take a
small amount of tissue that relates to the area of interest and perform a standard
proteomic analysis using cell and tissue lysates.

Traditional approaches to biomarker purification and sequencing using tissue
lysates include liquid chromatography followed by MS (LC-MS) as well as traditional
SDS PAGE followed by gel band excision and tryptic digestion. In this type of
experiment, care must be taken to ensure that the peptide or protein species detected in
the direct tissue analysis are being adequately represented in tissue lysates. Methods of
microdissection such as LCM can be an important first step in creating a lysate
representative of cells containing the biomarker of interest. However, fractionation
schemes, almost always necessary for the simplification of complex protein mixtures
before MS/MS analysis, increase the sample amount requirements and consequently the
time needed to obtain enough material using LCM. Bulk tissue lysates can be used as an
alternative if the tissue contains greater than 90% of the cell population of interest.
Any sequence identification of potential biomarkers via mass spectrometry should
also be confirmed using affinity detection methods such as Western blot or
immunohistochemistry. For many human proteins commercially available antibodies
make this kind of confirmation experiment routine and rapid. For peptides or proteins for
which no antibody is available or for unknown proteins from species without a complete
database, antibodies must be generated to verify results.
In this Aim we purified and identified the sequence of the ion m/z 4355. Using
basic chromatography capture, we reduced the complexity of prostate tissue lysates to
enable the use of MALDI-TOF tandem MS (LIFT). Using direct in-situ trypsinization the
sequence was also verified by the detection of specific peptide fragments. Finally, the
identity of the biomarker protein was verified using immunohistochemistry and Western
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blot analysis. Additional protein species present in prostate tissues were also sequence
identified.

4.2 Materials and Methods
Materials
Rabbit monoclonal antibody to MEKK2 (EP626Y) was purchased from Abeam,
Cambridge, MA. Rabbit polyclonal antibody to MEK 5 (RB0932) was purchased from
Abgent, San Diego, CA.

Tissue and cell culture lysates
Tissue lysates were prepared from bulk frozen prostate tissue (~0.5mm ) by
homogenizing the samples in a small dounce tube on ice with a solution of 20mM Hepes,
1% Triton-X 100 (1ml). Lysates were then sonicated at room temperature for 15 minutes
and spun down at 14,000 rpm for 2 minutes to remove cellular debris. The lysates were
then subjected to fractionation using weak cationic exchanger (WCX) magnetic beads
(Bruker Daltonic) according to the supplier's specifications. The bound peptides and
proteins were eluted in 20 ul of elution buffer. Five microliters of this eluate was
lyophilized and resuspended in 5 ul of CHCA matrix in 50% acetonitrile with 0.1% TFA.
Lysates from the prostate cancer cell lines (Dul45, LnCap and PC-3) were prepared from
106 cells in a lysis buffer containing 0.3% SDS, 3%DTT and 30mM Tris pH 7.5
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MALDI-MS/MS and Protein Identification
One microliter of each tissue lysate mixed with matrix was then spotted on a steel
MALDI target. The mass profiles were recorded by MALDI MS using the same
acquisition parameters as for tissue imaging. Data was collected on the UltraFlex III in
reflectron mode to verify the presence of the peak of interest. MS/MS analysis of the
peak was then performed in LIFT mode. An optimized high mass LIFT method was used
and externally calibrated with fragments from a peptide standard with parent masses in
the mass range of 700-4500 Da . A parent mass (monoisotopic mass as determined in
reflectron mode) was selected and LIFT analysis (MS/MS) was performed in the
Ultraflex TOF-TOF. Peaks were labeled using FlexAnalysis software and opened in
BioTools 3.1 (Bruker Daltonic) The MS/MS spectrum sequence analysis and database
search was performed using MASCOT 2.2.03 with the following settings: MS Tolerance:
70 ppm MS/MS Tolerance: 1.0 Da, no enzyme designation, serine acetlyation, using the
National Center for Biotechnology Information database for human sequences with
20,080,125 entries.
Trypsin digestion was performed on the tissue slices (lOum) by spotting 0.5ul of
a solution of 0.769ug/ul trypsin in 50mM Ammonium bicarbonate pH. 8.0. The tissue
slices were then incubated at 37°C for 2 hours. Following trypsin treatment the tissue
sections were spray coated with CHCA (7mg/ml in 50% acetonitrile, 0.2% TFA). Data
was collected across the tissue in reflectron mode.
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Immunohistochemistry
Immunostaining of UMFix treated paraffin-embedded and frozen, specimens was
performed by the avidin-biotin peroxidase complex method using the Vectastain Elite
ABC kit (Vector, Burlingame, CA). Blocking was performed with an avidin-biotin
blocking kit (Vector Laboratories, catalog number SP-2001). Fixed and frozen tissues
were then treated with 0.3% hydrogen peroxide to block endogenous peroxide activity for
15 minutes. Sections were incubated in normal goat serum to block nonspecific binding
for 20 minutes at room temperature. Sections were incubated with rabbit monoclonal
antibody to MEKK2 diluted 1:50 in PBS or rabbit polyclonal antibody to MEK5 for 1
hour at room temperature. This antibody reacts with the N-terminal portion of MEKK2.
Sections were then treated with biotinylated goat anti-rabbit immunoglobulin G (IgG),
followed by treatment with avidin-biotin-peroxidase complex, and stained with IMPACT
DAB peroxidase substrate (Vector Labs) according to the supplier's protocol.
Counterstaining was performed with Mayer's hematoxylin.

Western Blot Analysis
A total of 30-100ug of protein was separated on a 4-12% SDS-PAGE gel and
transferred by semi-dry transfer method to PVDF membranes (Immobilon-P, Millipore,
Billerica, MA). The membranes were then incubated in Odyssey™ blocking buffer
diluted 1:1 in PBS for 1 h at room temperature. Incubation with rabbit monoclonal
antibody to MEKK2 (EP626Y) diluted 1:1000 in blocking buffer was performed
overnight at 4°C with gentle shaking. Blots were then washed four times with 5 min
incubations in PBS and 0.1 % Tween 20 (PBST). The secondary antibody, Alexa Fluor
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IRDye 800cw goat anti-rabbit IgG (# 926-32211), was diluted 1:5000 with blocking
buffer, 0.1% Tween 20, and 0.01% SDS. The membrane was incubated with 10 ml of this
solution with gentle rotational mixing at room temperature for 1 h protected from light.
The membranes were then washed in PBST as before, washed in PBS and scanned with
the Odyssey infrared imaging system (LI-COR, Lincoln, NE).

4.3 Results
Sequence Identification of m/z 4355 as a fragment of MEKK2
Having established the differential expression of a peptide ion at m/z 4355 in specific
Aim 1, we next set out to sequence it. Lysates were prepared from 4 tissue samples; 2
PCa and 2 benign prostate. These tissues were examined in the initial MALDI-IMS
analysis and found to have high or low expression of the peak at m/z 4355. Protein
lysates were incubated with weak cationic (WCX) magnetic beads and eluted fractions
were shown to be enriched for the m/z 4355 peak as measured by MALDI-TOF. As seen
in Figure 19, the peptide ion captured from the WCX fractionation of the PCa tissue
lysate matches the mass detected directly from the tissue within an error of 0.26 Da,
whereas no peptide ion was detected at this m/z in the enriched lysate from benign tissue.
The PCa lysate was then concentrated via lyophilization and prepared for MS/MS
analysis as described above. Figure 20 displays the fragmentation pattern of the parent
ion (m/z 4350.4), in which it can be seen that the spectra contained many large internal
fragments observable in the TOF/TOF analysis. The fragmentation series gave a
MASCOT top score of 67 (1.0 Da, 70 ppm), with scores > 63 indicating extensive
homology, and matched to a fragment of MEKK2 (Swiss-Prot entry Q9Y2U5) with S-
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acetylation at the N-terminal of the peptide (Figure 21). Out of 129 observed fragment
peaks, 126 could be accurately assigned to theoretical fragments of MEKK2. This
sequence represents amino acid residues 26-61 in the 619 amino acid full-length
sequence and lies within the PB1-domain of the molecule.
In order to further establish that the m/z 4355 ion derived from tissue is a
fragment of MEKK2 we performed an on-tissue digest to analyze for the presence of
predicted MEKK2 tryptic fragments. A tissue section previously found to have high
expression of the m/z 4355 peak in a PCa region was used for this analysis. Serial
sections of the same tissue region were harvested and analyzed. One of the mirror
sections was trypsin treated while the adjacent mirror section was untreated and used as a
control. Ion density maps were also generated using the indicated theoretical tryptic
peptides. As seen in Figure 22, specific theoretical masses of the predicted MEKK2
fragment after trypsinization could be detected in the trypsin treated PCa tissue. The intissue trypsin-generated fragments matching the theoretical digest masses were not
present in the mirror untreated section of the same PCa tissue (Figure 22C). Furthermore,
trypsin digestion of benign tissue sections did not generate fragment ions corresponding
to theoretical MEKK2 cleavage products (Figure 22B). Unfortunately, the peptides were
not of sufficient abundance to perform tandem MS. We also show a representative ion
density map image derived from the parental 4355 m/z as a comparison to images derived
from the tryptic peptides (Figure 22A). This analysis demonstrates that both the parental
peptide and predicted peptide fragments display concordant tissue expression.
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Other Proteins Sequenced from Prostate Tissue
In our efforts to sequence the ion at m/z 4355, we were also able to sequence
many other proteins expressed in prostate tissue using MALDI-TOF tandem MS. While
we cannot make a determination on the comparative expression levels of these peptides
and proteins in PCa versus benign tissue, their presence and the ability to sequence them
directly from the tissue samples represents an important step in both biomarker discovery
and identification. The results of this effort can be seen in Table 6. Using both the bulk
PCa tissue lysate and the WCX fractionated lysate we were able to identify 4 additional
proteins. Actin and hemoglobin are common proteins found in tissue, and alpha-1
antitrypsin is an abundant serum protein. Direct tissue trypsin digestion enabled the
sequencing of abundant and less abundant proteins. A total of 20 additional proteins were
sequenced from the trypsinized tissue. Of note are transgelin (found in benign and PCa
tissue) and prokineticin-1 (found in PCa tissue). Transgelin (also known as SM22) is
found in vascular and visceral smooth muscle and is an early marker of smooth muscle
differentiation [181]. It is also present in fibroblasts, and some epithelium where
expression is likely driven by TGF-betal [182]. Prokineticins (PK-1 and PK-2) are a
novel family of secreted peptides with diverse regulatory roles, one of which is their
capacity to modulate immunity and promote angiogenesis [183, 184]. Prokineticin-1
(PK1) is also known as endocrine gland-derived vascular endothelial growth factor (EGVEGF).
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MEKK2 is Overexpressed in PCa Specific Regions of the Prostate
We examined the expression of MEKK2 in PCa tissue using
immunohistochemistry specific for expression of MEKK2. PCa containing and adjacent
uninvolved frozen tissues were stained for the detection of MEKK2. The antibody used
is specific for the N-terminal portion of the MEKK2 protein where the PB1 domain is
located and our fragment lies [185]. As seen in Figure 23A, MEKK2 staining correlates
with the presence of PCa in the tissue section. Additional prostate tissues were also
stained and magnified views of the stained PCa glands can be seen in Figure 23B. All
prostate tissues examined showed high levels of MEKK2 within involved tissue with a
predominantly cytoplasmic expression pattern. In contrast benign glands displayed much
reduced MEKK2 expression that was only slightly above background levels obtained
with no primary antibody.
Samples of high grade PCa can be difficult to obtain due to the success of early
detection screening practices. We were able to obtain a total of three poorly differentiated
tissue samples and observed reduced expression of both the m/z 4355 ion and MEKK2 in
these three cases. As shown in Figure 24, overall very little of the ion at m/z 4355 is
present in two cases of PCa with Gleason scores of 4+5 and one case with a Gleason
score of 4+4. The IHC staining for MEKK2 of another tissue sample from the same
prostate (Gleason 4+4) can be seen in Figure 25. Overall there is not a large amount of
m/z 4355 ion present or MEKK2 staining evident. However, a small foci of m/z 4355
expression is visible in the MALDI-IMS image (red area). This foci corresponds to the
same area which produced dark staining for MEKK2 evident in the intra-luminal space of
one gland.
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Figure 19. Purification of PCa biomarker at m/z 4355. Representative spectra from
direct acquisition from tissue showing the peak profile of m/z 4355 in: A)-linear mode
B)-reflectron mode. Also shown are the reflectron mode spectra from the corresponding
tissue lysates from benign tissue (C), and PCa containing tissue (D)
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Figure 20. Sequence identification of biomarker peak m/z 4355. MS/MS spectra of
monoisotopic peak of m/z 4355 (m/z 4350.4) from prostate tissue lysate collected using
TOF/TOF LIFT. Peaks attributed to internal fragments are labeled. Out of 129 peaks 126
were assigned. A Mascot search identified the sequence as matching to the PB-1 domain
ofMEKK2.
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Probability Based Mowse Score
Individual ions scores > 44 indicate peptides with significant homology.
Individual ions scores > 63 indicate identity or extensive homology (p<0.05).
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Figure 21. Protein sequence identity of m/z 4355 ion. A Mascot search identified the
sequence as matching to the PB-1 domain of MEKK2 representing sequence coverage of
36% for this region.
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Figure 22. On-tissue trypsin digestion of PCa tissue detects predicted peptides of MEKK2 fragment. A) H & E stained
image of PCa tissue with a region of adenocarcinoma circled (top), and MALDI-IMS showing spatial distribution of
parent ion at m/z 4355 (bottom). B) After trypsin treatment on the tissue, 4 predicted fragments corresponding to the
MEKK2 fragment sequenced were detected in the PCa tissue. Control is an identical section of PCa tissue without
trypsin treatment. A benign section of prostate tissue was also trypsin treated. C) Representative spectra from trypsinized
(top) and non-trypsinized (bottom) PCa tissue showing the presence of an ion at m/z 631.3 in the trypsin treated tissue
only. D) The sequence of the peptide corresponding to the m/z 4355 is shown below for reference with trypsin cleavage
sites (R and K) shown.
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Expression of MEKK2 in Prostate Cancer Cell Lines and Tissues
Western blot analysis was performed on PCa and benign tissue extracts and 3
prostate cancer cell lines (Dul45, LnCap, PC-3). LNCaP cells originate from a lymph
node metastatic lesion of human PCa and Dul45 and PC-3 are human prostate
adenocarcinoma cell lines metastatic to the brain and bone respectively. The antibody
used was the same as that employed in the above IHC analysis for MEKK2 expression.
The relative expression of MEKK2 in these systems is shown in Figure 26. All three
prostate cell lines showed strong expression of full length MEKK2 (70kDa). This
analysis revealed higher MEKK2 expression in the PCa tissues when compared to the
expression seen in the benign tissues. Densitometry analysis indicated a 4.4 fold
increased expression of MEKK2 in PCa tissue compared to benign tissue.

MEK5 Expressed in PCa and Benign Prostatic Tissue.
To investigate members of the ERK5 pathway downstream from MEKK2, we
also performed IHC for MEK5 in 3 PCa and 3 benign prostate tissues. As seen in Figure
27, MEKK2 expression correlates with MEK5 expression however there are distinct
abundance differences with respect to Gleason grade. MEKK2 expression in the
moderately differentiated PCa (Gleason 3+4) is higher than MEK5. Conversely, MEK5
expression appears somewhat higher in the higher grade PCa tissue (Gleason 4+4 and
4+5). Additionally, MEKK2 expression is barely detectable in benign prostate, but
MEK5 nuclear staining can be seen in a few glands. In cases with cystic atrophy MEKK2
and MEK5 staining is evident in the intra-luminal spaces. The MEK5 staining of the
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luminal cells appears to be both cytoplasmic and nuclear, whereas MEKK2 staining is
predominately cytoplasmic.

4.4 Discussion
We have identified the ion at m/z 4355 found to be differentially expressed in PCa
tissue as a fragment of MEKK2 and confirmed the differential expression of this protein
between tumor and benign tissue using immunohistochemistry and Western blot analysis.
MEKK2 is a member of a mitogen activated protein kinase cascade (MAPK) and is
designated as a MAP kinase kinase kinase or MAP3K. Mitogen-activated protein kinase
(MAPK) signaling cascades are among the most widespread signaling mechanisms
involved in eukaryotic cell regulation. MAPKs are activated through a module that
includes a MAPK, a MAPK kinase (MAPKK), and a MAPKK kinase (MAP3K). Thus a
MAPK cascade consists of three sequential protein kinase reactions which finally lead to
the phosphorylation of defined MAPK substrates (e.g., transcription factors, other protein
kinases, phospholipases, cytoskeleton- associated proteins) on serine/threonine residues
[186-188]. Biochemical and genetic studies have demonstrated that MAP3Ks are crucial
in relaying distinct cell-surface signals through various downstream MAPK pathways
[187]. The MAP3Ks are the most numerous of the core kinase elements. The challenge is
in defining the specific upstream inputs and cellular functions mediated by each.
Additionally, MAP3Ks have been found to be highly promiscuous, interacting with and
activating a number of downstream components and are the major players in the
coordination, localization, duration and magnitude of MAPK activation in response to
cell stress and inflammation [189]. The in vivo functions of MEKK2 have been studied in

Table 6. Sequence Identification of Protein Peaks Found in Prostate Tissue
Peaks identified from bulk PCa tissue Ivsates
Actin a-2
1617.8
Actin a-1
2952.4
Hemoffobin subunit-a
3586.6

Expect
0.022
0.00053
6.3 x 10' 8

MASCOT score
60
79
112

Peaks Identified from WOC purified PCa Ivsate
Alph a-1-antitrypsin
4133.4
MEKK2
4350.4

6.0 xlO" 6
0.0011
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Peaks identified fromtrvpsiniied bentert prostate tissue
Dynein-heavy chain
854.6
Calponin t
993.5
amyloid (5 A4 precursor protein-binding
1032.6
1046.7
28smitochondrial ribosomal protein S2
Kine sin-like protein
1055.5
1155.5
GDNF family receptor-a like
USP6 N-terminal like protein
1209.8
Actin smooth muscle
1354.6
Transgelin
1408.6
Phosphoinositide-3 kinase regulatory subunit
4130.1
Actin smooth muscle
1790.9
1932.9
Cartiladge acidic protein 1
Desmin
2088.7
3458.5
Poly [ADP-ribose] polymerase 12

0.047
0.031
0.0017
0.03
0.044
0.0099
0.0023
0.00026
3.0 xlO" 6
0.033
0.00014
0.0098
1.8 xlO" 6
0.018

13
32
41
17
23
40
41
55
72
15
54
35
74
27

Peaks identified from trvostnized PCa tissue
656.1
Myosin phosphatase targeting subunit
Actin smooth muscle
976.5
Actin smooth muscle
1198.9
1209.7
Prokineticin-1
Transgelin
1407.9
(D)J recombination-activating protein 2
1978.3

0.011
0.00049
0.0022
0.044
0.00021
0.00098

25
49
39
29
52
46
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different physiologic systems, including MEKK2 knockout mice and cells. The pathways
in which MEKK2 plays a part can be seen in Figure 28. Studies have shown that MEKK2
regulates T-cell function [190-192], controls cytokine gene expression in mast cells and
mediates epidermal growth factor (EGF) receptor and fibroblast growth factor-2 (FGF-2)
receptor signals [193,194], and plays a role in rheumatoid arthritis [195,196]. In
addition, MEKK2 activation is critical for c-Jun-N-terminal kinase (JNK) activation and
TNF-a production [197].
MEKK2 and MEKK3 are two closely related MAP3Ks belonging to the
MEKK/STE11 subfamily which are expressed in multiple tissues and are also potent
activators of the NFkB, ERK5 and JNK pathways [192, 198]. In fact, MEKK2 is one of
only two of the 20 known MAP3Ks, the other being MEKK3, which regulate the
mitogen/extracellular-signal-regulated kinase kinase 5/ extracellular signal-regulated
kinase-5 (MEK5/ERK5) pathway [199-201]. Growth factors and oxidative/osmotic
stress stimulate a three-tier ERK-5 kinase module consisting of MEKK2/3, MEK5 and
ERK5. MEKK2 and MEKK3 contain PB1 (Phox-Bemlp) domains that selectively
heterodimerize with the MEK5 PB1 domain to form a functional MEKK2 (or MEKK3)MEK5- ERK5 ternary complex [202, 203]. PB1 sequences are
dimerization/oligomerization domains present in adaptor and scaffold proteins as well as
kinases [204]. PB1 domain-dependent MEKK2/3-MEK5 heterodimers provide a spatially
organized signaling complex primed to activate ERK5 in response to activation of
MEKK2 or MEKK3 [200]. No other MAPK cascade has been shown to form such a
complex. Interestingly, the m/z 4355 represents a peptide fragment that lies within the
PB1 domain and may reflect molecular pathway changes indicative of PCa development.

ERK5 signaling is a critical pathway in the regulation of cell invasion under
"normal" conditions to support immune surveillance as well as during tumor metastasis
(reviewed in [205]). Indeed, the ERK5 pathway has been implicated in high grade
prostate cancer. Specifically, an increase in MEK5 expression was associated with
metastatic prostate cancer, cell proliferation, MMP-9 expression and cell invasion [206].
Strong MEK5 expression was also found to correlate with the presence of bony
metastases and less favorable disease-specific survival. An additional report found
significant correlation between ERK5 cytoplasmic overexpression, Gleason sum score
and less favorable disease-specific survival [207]. The authors also found that ERK5
nuclear expression is significantly associated with the transition from hormone-sensitive
to hormone insensitive disease. Our studies have also found MEK5 expression in PCa
tissue detected via immunohistochemistry. MEK.5 protein expression correlated with
MEKK2 expression although the level of expression varied with PCa Gleason score.
Cases of well to moderately differentiated PCa showed a higher level of MEKK2
expression as compared to MEK5. The situation was reversed in high grade or poorly
differentiated PCa in that MEKK2 levels decreased and MEK5 expression increased.
This is in agreement with previous studies in which MEK5 was over-expressed in high
grade PCa. We also detected MEK5 expression in some benign prostate tissues,
especially in atrophic glands, although not at the level seen in high grade PCa. Overall
MEKK2 staining was predominately cytoplasmic and MEK5 staining was predominately
nuclear. This is consistent with a recent study in which MEK5 is localized in the nucleus
of HeLa and Rat-1 cells both before and after stimulation [208]. This study also reported
that in resting cells, MEKK2 was localized all over the cell, and upon stimulation of the

cells with EGF there was an enrichment in the nuclear localization of MEKK2.
Since MEK5 lies downstream of MEKK2 in the ERK5 pathway, our findings
imply that the ERK5 pathway is highly active in PCa cells. Although ERK5 and MEK5
have been shown to correlate with high grade PCa disease, this is the first time MEKK2
has been shown to discriminate between cancer and normal prostate tissues.
Unfortunately, we were unsuccessful in our attempt to perform Western blot analysis for
MEK5 and ERK5 (data not shown). Since MEKK2 has been shown to also play a part in
both the ERK1/2, JNK, and p38 and pathways, as well as NFKB activation, further
studies are needed to determine the exact role MEKK2 is playing with regard to
carcinogenesis and which pathway(s) are increasingly activated.
Several studies have found MEKK2 over-expression in the synovial tissue and
cultured synovocytes of arthritis patients [196, 209]. In vitro kinase assays have shown
that MEKK2 kinase activity is increased by cytokines in synoviocytes [196]. MEKK2
seems to play an important role in cytokine production and is known to directly
phosphorylate and activate Ikappa B kinases, playing a role in the pro-inflammatory
transcription factor nuclear factor kappa B (NFKB) signaling pathway by controlling the
late phase of its induction [210]. Furthermore it has also been shown that ERK5 may
enhance NFKB activity by enhancing p65 nuclear localization [211]. Thus the increase in
MEKK2 protein levels may increase NFKB activity directly or indirectly through its role
in activating ERK5 signaling.
As mentioned before, inflammatory disorders harbor a greatly increased risk for
cancer development, owing primarily to the pro-growth environment generated by

Figure 23. MEKK2 expression in prostate tissue. A) Immunohistochemical analysis of frozen prostate
tissue sections. H&E stained prostate tissue with regions of PCa circled (left panel). MEKK2 stained
serial section showing staining in PCa regions (middle panel). Control section without primary
antibody (right panel). B) Representative areas of MEKK2 staining from 6 PCa and 3 benign adjacent
tissues showing strong expression of MEKK2 in adenocarcinoma cells and little expression in benign
glands.
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Figure 24. Representative MALDI-IMS from High Grade PCa. Two frozen PCa tissue
samples, both with a Gleason score of 4+5 were processed for MALDI-IMS. Top panels
show the absence of a peak at m/z 4355 and the middle panels show no expression visible
in the resulting MALDI-IMS images. Bottom panels are the H&E stained tissue images.

Figure 25. MALDI-IMS of m/z 4355 and IHC for MEKK2 in High Grade PCa. One
frozen PCa tissue sample with a Gleason score of 4+4 was processed for MALDI-IMS.
A) H&E stained section with area of PCa circled. B) Resulting MALDI-IMS image with
a small area of high expression of the ion at m/z 4355 which correlates with intense
MEKK2 staining of the same area in a serial section shown in (C). D.) 10X view of the
area with intense MEKK2 staining showing intra-luminal expression.

Benign

PCa

Figure 26. Western blot analysis for expression of MEKK2. Western blot of the
indicated PCa cell lines (30ug) and tissue lysates (lOOug) was performed using an
antibody to the N-terminal region of MEKK2. Actin was used as a loading control. The
bottom panel is the densitometric quantitation of the MEKK2 bands for benign and PCa
tissue lysates.
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PCa(3+4)

Benign

PCa (4+4)

PCa(4+5)

Cystic atrophy

Cystic atrophy

Figure 27. Comparison of MEKK2 and MEK5 expression in prostate tissue.
Immunohistochemistry was performed, on three PCa tissues with increasing Gleason
scores (top panels) and three benign tissues, two with cystic atrophy (bottom panels).
MEKK2 expression in reduced in the higher grade PCa lesions compared to the lesions
with Gleason grade 3+4, whereas MEK5 expression is increased. Minimal expression of
MEKK2 and MEK5 is visible in the benign prostate epithelial cells. MEKK2 and MEK5
are also expressed intra-luminally in two cases of cystic atrophy. Note the cytoplasmic
expression of MEKK2 and the nuclear expression of MEK5.
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Figure 28. MAPK pathways in which MEKK2 plays a role. MEKK2 plays a role in the
ERK 1,2, JNK 1, 2, p38 and ERK5 pathways. Leading to growth, differentiation,
inflammation and apoptosis depending on which pathway and cell system is activated.

activated inflammatory cells [212]. Since NFKB has been identified as an important
molecule linking chronic inflammation [213] and cancer it is tempting to speculate about
the contribution of MEKK2 to inflammation and the development of prostate cancer,
because of its contribution to both NFKB and JNK activation. Indeed our study has
uncovered over-expression of MEKK2 in proliferative inflammatory lesions of the
prostate (PIA) and lesions exhibiting cystic atrophy. Inflammatory responsive cells have
previously been found juxtaposed to PIA lesions. These include mononuclear and/or
polymorphonuclear inflammatory cells in both the epithelial and stromal compartments,
and sometimes, abundant macrophages and/or neutrophils in the glandular lumen or
epithelium [214]. Macrophages may be present in the lumen of PIA lesions to engulf
epithelial cells damaged by infection, oxidants, autoimmunity or hypoxia. In turn
macrophages and neutrophils secrete cytokines, tumor necrosis factor and reactive
nitrogen species leading to an environment susceptible to chronic infection.
The examination of high grade PCa tissue samples in our study found a reduction
of detectable MEKK2 in both MALDI-IMS (m/z 4355) results and IHC staining.
Interestingly, in prostate cancer as in many other malignancies, an overall reduction in
tumor stroma indicates a more malignant pathological grade [215]. It is conceivable that
an overall reduction in specific stromal cells within high-grade lesions leads to reduced
potential for specific stromal cell mononuclear cell interactions that are supportive of
antitumor cytotoxic activities and secretion of pro-inflammatory mediators. It has been
established that in the tumor microenvironment, there is a delicate balance between
antitumor immunity and tumor-originated proinflammatory activity, which weakens
antitumor immunity [216]. The inflammatory milieu is occupied by cells such as resident

and recruited macrophages, dendritic cells, T cells, and NK cells [217]. Among these,
tumor-associated macrophages (TAMs) and T cells are frequently the prominent
leukocytes present in a tumor [212, 218]. The infiltrated immune cells can exert
paradoxical effects during cancer development [219]. These effects depend on different
mediators that are released by host inflammatory cells, cancer cells, as well as fibroblasts
and endothelial cells. When host-mediated antitumor immunity is stronger than tumormediated immunosuppressive activity, tumor cells can be eliminated [220]. Conversely,
when host-mediated antitumor activity is weaker than tumor-mediated
immunosuppressive activity, tumor cells undergo immune escape and grow rapidly [220].
Given the fact that some of the tissue we examined contained only high grade
adenocarcinoma cells, the potential for interaction with immune cells is greatly reduced.
Indeed, we did not observe many infiltrating lymphocytes in the high grade PCa tissues
examined, leading to speculation that there is no longer a mechanism whereby an
inflammatory response is potentiated, leading to a possible reduction in MEKK2
expression.
Our sequence identification of other proteins directly from trypsinized tissue
yielded some interesting results. Transgelin (SM22) has been widely reported to be
abnormally expressed in many solid tumors [221]. Recent evidence suggests that
transgelin acts as a tumor suppressor and its expression has been found to be reduced in
high grade prostate, breast and colon cancers [222, 223]. Transgelin also represses MMP9 expression, by reducing AP-1-dependent trans-activation of the gene by way of
compromised ERK activation [181]. Diminished transgelin expression in several cancers
may therefore be responsible for elevated MMP-9 expression evident in some tumors. In
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our study, transgelin was identified from both PCa and benign tissue. Further studies for
the determination of the relative expression levels of this protein and/or peptide using
MALDI-IMS may reveal altered expression levels. Another protein sequenced in this
study found only from PCa tissue is PK-1 or EG-VEGF. PK-1 does not belong to the
VEGF family but instead is a member of a structurally related class of peptides which
includes the digestive enzyme colipase [224]. PK1 and -2 exert their physiological
functions through G-protein-coupled receptors recently identified and named PK receptor
type 1 (PKR1) and type 2 (PK-R2) [183]. These receptors are activated by nanomolar
concentrations of recombinant PK. Activation of PK receptors induces calcium
mobilization, induction of phosphoinositide turnover, and activation of MAPK signaling
pathways [225]. PK-1 is a key mediator of angiogenesis and exposure of human or mouse
hematopoietic stem cells to PK-1 results in significant increases in total leukocyte,
neutrophil, and monocyte counts [226]. Emerging evidence indicates that prokineticins
are associated with pathologies of the reproductive and nervous systems, myocardial
infarction as well as tumorigenesis (reviewed in [184]). A recent study demonstrated that
prokineticins and their receptors are expressed in human prostate and that their levels
increased with prostate malignancy [227]. This may imply that PK1 could be involved in
prostate carcinogenesis, probably in the regulation of angiogenesis. Therefore, PK-1 may
be an interesting biomarker warranting further investigation.
The identification of a peptide fragment of MEKK2 leads to speculation as to how
this fragment was formed. It is possible that this fragment is a degradation product
formed during tissue processing. Prostate tissues are known to have a general increase in
overall proteolytic activity during tumor progression, especially in the metalloprotease
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and cysteine protease classes [228]. Serine proteases are also highly abundant in prostate
tissues (i.e. PSA and other members of the kallikrein family) [229]. Since the MEKK2
fragment we sequenced has a serine at the N-terminus the increased presence of the
fragment in areas of cancer could be a result of non-specific cleavage of the full-length
MEKK2 protein by a serine protease occurring either as a natural process or after tissue
harvest. Over-expression of the full-length MEKK2 (70kDa) was visible in the PCa tissue
lysate in our Western blot however, so not all of the protein is cleaved. Alternatively, the
fragment could be generated from the targeted and specific cleavage of MEKK2 due to
an unknown disease specific mechanism. For example, MEKK2 is a substrate of Smurfl,
an E3 ubiquitin ligase. Smurfl physically interacts with MEKK2 and promotes the
ubiquitination and turnover of MEKK2 to promote osteoblast activity and bone
homeostasis [230]. Proteasome degradation of ubiquitin-targeted proteins is an important
mechanism that negatively controls activated signaling pathways. Another study found
that following TNF-a stimulation of human embryonic kidney cells, XIAP (a regulatory
protein of N F K B ) interacts with and ubiquitinates MEKK2, promoting a second wave of
nuclear translocation that leads to prolonged N F K B activation [231]. This opens up the
intriguing possibility that NFKB activation and therefore the inflammatory stimulus is
perpetuated in early tumor development. Further functional studies of MEKK2 in prostate
tissue will be needed to access the regulatory mechanism (if any) that lead to the
generation of the fragment we are detecting in early prostate cancer.

CHAPTER V
AIM 3: EVALUATION OF THE CLINICAL UTILITY OF
MALDI-IMS BIOMARKERS

5.1 Introduction
The ultimate hurdle for any new biomarker is validation. In some respects,
biomarker validation is more arduous than discovery [232]. Unfortunately, the literature
is full of novel marker candidates that did not stand up to validation [233]. Biomarker
validation faces several big challenges. One is the biological variability of patients'
samples. Another issue is that single biomarkers are unlikely to provide the sensitivity
and specificity needed for most clinical applications given the substantial heterogeneity
among cancers. It is therefore unrealistic to expect that a single biomarker will provide
information about tissue type and malignant transformation throughout the various stages
of tumor development and progression. Therefore, panels of biomarkers are needed. This
makes the validation of a single biomarker all the more challenging. Furthermore, in
order for cancer biomarker tests to be used effectively in a clinical setting, their clinical
risks and benefits must be assessed. For example, if a biomarker detects disease early,
there are several reasons why it might not have an overall benefit for the screened
population [234]. These include ineffective treatments for detected tumors and
difficulties with implementing the biomarker detection in clinical laboratories (ease of
use or prohibitive economic factors). For studies where the identities of the biomarkers
are known, results should be validated using an independent sample set, either using the
original technique or an alternative assay such as an immune-based assay or array. For
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studies using computer-based models of profiles in which the identity of the biomarkers
is unknown, it is essential that the model be validated with an independent test set of
samples analyzed during a completely separate time period [235]. There are three
common ways biomarkers are validated: 1) validation to confirm results, 2) validation to
expand utility, and 3) validation to determine clinical usefulness. Most discovery
laboratories can perform the first two validation tasks however the third task usually
requires several laboratories and many hundreds of samples.
In this Aim we use a cohort of surgery specimens to evaluate the clinical utility of
the m/z 4355:MEKK2 fragment biomarker and protein expression patterns. A new cohort
of tissue samples were analyzed blinded and the diagnosis based on MALDI MSI
imaging werecompared with the diagnosis made by clinical laboratory pathologists. The
classification algorithms developed in Aim 1 using multiple m/z values were also used for
the classification of the tissue samples as PCa or benign or metastatic.

5.2 Materials and Methods
Sample selection and processing
Twenty five tissue samples from prostatectomy specimens were collected and
embedded in OCT and processed as described in Aim 1. Regions of interest were circled
by a pathologist on the serial sections stained with Hemotoxylin and Eosin. In addition, 8
UMFix treated tissues were also collected and processed as previously described. Tissue
sections were mounted on ITO coated slides and prepared with SPA matrix using the
same protocols used in Aiml. All tissue diagnoses were blinded to the investigator until
after the collection of the data and export of the spectra.

MALDI-IMS
MALDI-IMS was performed as previously described in Aiml. Images were
acquired using both BioMAP and Flex-Imaging.

Classification of Tissue Specimens
Spectra were exported from regions of interest and classified using ClinProt tools
software and the algorithms developed in Aiml. The normalized intensity values of the
m/z 4355 (MEKK2 peak) were also calculated using ClinProt tools for each blinded
tissue sample. The classification results of both the algorithms and the ROC cut-off
values for the m/z 4355 peak were compared to the diagnosis made by the clinical
laboratory pathologists.

5.3 Results
Classification of Blinded Dataset
A total of 29 frozen tissue areas representing 10 PCa, 10 benign distal and 9
benign adjacent samples were analyzed using MALDI-IMS. Additionally 8 UMFix
processed tissues (4 PCa and 4 benign) were also analyzed for validation. These
specimens were blinded to the investigator during the data collection and analysis phase.
A genetic algorithm using 5 peaks from the initial cohort was tested in its ability to
correctly classify blinded tissue samples. In the initial study cohort a high percentage of
PCa regions were correctly classified (90.3%), but the algorithm did not perform well on
the classification of benign tissues with only 64.1% correctly classified. For the blinded
samples, (9/10) 90% of the PCa tissues were correctly classified, whereas, only (3/19)
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15.8% of the benign tissues were classified correctly (see Table 7). For the UMFix
treated samples once again the genetic algorithm did not perform well in the
classification of the benign samples. As seen in Table 8, in a total of 8 UMFix treated
tissues, 62.5% of the samples were correctly classified. All of the UMFix treated PCa
tissues (4/4) were classified correctly, however only 1/4 (25%) of the benign tissues were
classified as benign.
The use of a cut-off value derived from the normalized intensity value of the ion
at m/z 4355 (MEKK2 fragment) performed much better in classifying the frozen blinded
samples. As shown in Table 7, using a cut-off of value of 27 for normalized intensity
derived from the ROC analysis, 82.7% of all the blinded samples were classified
correctly. This represents a correct classification of 80% for PCa tissue areas, and 84.2%
for benign areas (both adjacent and distal). Additionally, all of the 8 UMFix blinded
tissues were classified correctly using this ROC cut-off value indicating that the fixed
tissue preserves the peak intensity as well as the frozen tissue (Table 8).

5.4 Discussion
The validation of the biomarkers discovered in Aim 1 and 2 of this project were
tested in an independent set of samples. Using a genetic algorithm and normalized
intensity values for m/z 4355 (MEKK2 fragment) developed from the initial study cohort
the classification of the blinded samples was determined and compared to the
pathologist's histopathological diagnosis. The performance of the genetic algorithm to
correctly classify the samples was much poorer than the use of normalized intensity
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Table 7. Frozen Blinded Sample Classification Based on Normalized Intensity of m/z
4355 and Classification Algorithm
m/z 4355 Norm.
Int.*
Classification
Benign
19.0
Benign
13.9
20.3
Benign
17.5
Benign
25.6
Benign
24.1
Benign
114.1
PCa
56.1
PCa
48.2
PCa
24.6
Benign
25.1
Benign
24.9
Benign
48.5
PCa
29.8
PCa
17.7
Benign
76.9
PCa
20.9
Benign
33.9
PCa
22.4
Benign
57.0
PCa
42.4
PCa
22.0
Benign
46.2
PCa
35.9
PCa
Benign
19.1
24.2
Benign
26.7
Benign
21.9
Benign
17.9
Benign

1

Tissue
4340-2
4422-2
4597-1
4608-1
4691-2
4735-1
4903-1 a
4903-1b
4903-2a
4903-2D
4928-2
4941-1
4941-2a
4941-2b
4964-2
4966-1 a
4966-1 b
4966-2a
4966-2b
4974-1
4982-1 a
4982-1 b
4982-2
4989-1 a
4989-1 b
4994-1
4998-1 a
4998-1 b
5023-3

Pathology
Diagnosis
Benign Dist.
Benign Dist.
Benign Dist.
Benign Dist.
Benign Dist.
Benign Dist.
PCa
Benign Adj.
PCa
Benign Adj.
Benign Adj.
Benign Dist.
PCa
Benign Adj.
Benign Dist.
PCa
Benign Adj.
PCa
Benign Adj.
Benign Dist.
PCa
Benign Adj.
PCa
PCa
Benign Adj.
PCa
PCa
Benign Adj.
Benign Dist.

Correct
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes

Total Correct
PCa
Benign

82.7%
80.0%
84.2%

Algorithm
class.
Benign
PCa
PCa
Benign
PCa
PCa
PCa
PCa
PCa
PCa
PCa
Benign
Benign
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
PCa
Total Correct
PCa
Benign

Correct
Yes
No
No
Yes
No
No
Yes
No
Yes
No
No
Yes
No
No
No
Yes
No
Yes
No
No
Yes
No
Yes
Yes
No
Yes
Yes
No
No
41.4%
90.0%
15.8%

*Any value above 27 was considered indicative of PCa. This value was based on the optimal cutoff from the ROC curve. Bengn Dist= benign distal, Benign Adj.=benign adjacent
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Table 8. UMFix Blinded Sample Classification Based on Normalized Intensity of m/z 4355 and
Classification Algorithm

Tissue
4869-1
4885-2
4889-1
4913-1
4935-1
4987-1
4992-2
4994-1

m/z 4355 Norm.
Int.*
22.4
19.5
54.3
22.0
19.6
64.5
38.7
49.7

Classification
Benign
Benign
PCa
Benign
Benign
PCa
PCa
PCa

Pathology
Diagnosis
Benign
Benign
PCa
Benign
Benign
PCa
PCa
PCa

Total Correct
PCa
Benign

Correct Algorithm class. Correct
Yes
Benign
Yes
Yes
PCa
No
Yes
PCa
Yes
Yes
PCa
No
Yes
PCa
No
Yes
PCa
Yes
Yes
PCa
Yes
Yes
PCa
Yes

100.0%
100.0%
100.0%

Total Correct
PCa
Benign

62.5%
100.0%
25.0%

*Any value above 27 was considered indicative of PCa. This value was based on the optimal cutoff from the ROC curve.
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values. The apparent lack of specificity for the benign tissues in the blinded dataset points
out the weakness of a genetic algorithm to classify this type of data. Genetic algorithms
were initially employed for genomic microarray experiments and have been adapted for
proteomic dataset analyses [236, 237]. A genetic algorithm (GA) seeks to find a
collection of markers that separate cases and controls. Here the markers correspond to the
measurements at a given set of mlz values derived from the tissue specimen. Our study
employed a total of 36 PCa and 61 benign data for the training set. Typical spectra
produced from any individual tissue location produces from 50-200 peaks or features. In
multivariate predictive analysis, a statistical model or algorithm can be overfitted if it has
too many features for the number and type of cases in the training set [238]. This can
result in a model that fits the training data set very well but does poorly when applied to
other data as we saw in our blinded set. Another potential problem is that our data
analysis method involves exporting individual spectra from any given ROI. Based on the
size of the ROI, the number of exported spectra may be small or large. However, the
genetic algorithm does not average or take a consensus of each ROI, but treats each
spectrum as an individual. Therefore variations in the data may result in inaccurate
representation of features in each ROI.
Using the averaged normalized intensity value of the ion at m/z 4355 provided a
much better classification of the blinded tissue samples. One explanation for this
improved result is connected to how the data was calculated. After the spectra from each
ROI are exported, a normalized intensity value for each peak or feature was calculated.
The normalized intensity values from each individual spectrum were then averaged
across all of the representative spectra contained in any given ROI. This seems to provide
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a better representation and relative quantitation used for the classification. Indeed the
normalized intensity values were very consistent for benign and PCa tissue areas in both
frozen and UMFix processed tissue. Clearly better methods of quantitation and feature
selection are needed to improve the performance of different algorithms for their
application in MALDI-IMS experimental data sets. In reality, a sophisticated
classification system based on the use of both image and spectral feature selection will
probably provide the best classification model for this new technology. New methods
capable of combining different computational modules for processing histology images
have been developed recently [239]. A combination of these methods with other
classification algorithms should improve our results. Other classification algorithms
which have been used for MS data include Linear Discrimination Analysis (LDA),
Support Vector Machine (SVM), Classification and Regression Trees, Random Forest,
and Neural Networks [240]. Ultimately, each classification model may need to be
evaluated as to its applicability to MALDI-IMS data and a consensus classification could
be determined by combining two or more methods. The MALDI-IMS data generated in
future planned studies will provide the basis for adapting these new methods and
optimization of existing classification algorithms.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 AIM 1: The application of MALDI-IMS to prostate cancer diagnosis and
prognosis.
A. Our optimization of MALDI-IMS techniques determined that the use of an automated
spraying device for matrix coating of tissue sections is far superior to hand spraying for
reproducibility and consistency across multiple samples. Additionally, our results show
that UMFix processed tissue is compatible with MALDI-IMS in that both the spectral
qualities and images produced were comparable to those obtained from frozen tissue
specimens.

B. MALDI-IMS analysis of the study cohort of a total of 36 PCa and 61 benign tissue
sections derived from 59 patients resulted in the discovery of a protein expression profile
which discriminated PCa from uninvolved prostate tissue. The visual representation of
expressed discriminatory peaks resulted in images in which distinct areas of PCa could be
identified. A genetic algorithm was developed using 5 m/z values (3443, 3442, 4030,
4275, 4355) which could correctly classify 90.3% of the PCa containing regions, and
64.1% of the benign regions. The most differentially expressed peak (m/z 4355: p = 2.76
x 10"16) highly expressed in PCa tissue areas, was found to be discriminatory on its own,
with a normalized intensity value 2.5 fold above benign tissue expression. In a ROC
analysis, the optimal cutoff point for using the m/z 4355 peak as a biomarker for PCa in
tissue sections was a normalized average intensity value of 27. This cutoff point was
associated with a sensitivity of 75.0% and a specificity of 74.3% (AUC 0.834). It was
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also determined that tissue areas exhibiting distinct m/z 4355 expression also have
infiltrating lymphocytes surrounding cancerous glands as well as in areas designated as
proliferative inflammatory atrophy or cystic atrophy.

C. The examination of tissue derived from patients harboring micrometastatic disease
(n=12 case) resulted in the discovery of a unique expression profile differing from
matched PCa tissue harvested from patients with similar risk factors (n=7 control). We
developed a classification algorithm using 6 differentially expressed peaks (m/z 3374,
3751, 3817, 4030, 5364, and 5664) which was able to correctly classify the case PCa
tissues from benign at a rate of 83%. However, the algorithm's ability to correctly
classify tissue samples from patients without extra-prostatic spread (control) was only
58%.

6.2 Future Directions of Aim I
In Aim 1 we successfully optimized and refined MALDI-IMS methods, bringing
this technology one step closer to clinical utility. The use of UMFix for tissue fixation
allows the same tissue sample to be used for both patho-histological determination as
well as MALDI-IMS analysis. Our results have shown that UMFix is compatible with
MALDI-IMS analysis, and one aspect of future studies will focus on the long term
storage effects on tissue in this fixative and subsequent MALDI-IMS data quality.
The identification of a specific protein expression pattern for PCa tissue areas
resulted in images which closely match regions of interest circled by a pathologist. Any
new technology will only be useful to patient care if it is adopted by clinicians. In order
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for MALDI-IMS to be clinically useful it must contribute to the ability of pathologists
and surgeons to make accurate diagnosis and prognosis. Since pathologists are familiar
with the use of images to make diagnosis, the use of molecular images should translate
readily to this end. The greatest utility of tissue assessed biomarkers is restricted to
decisions made in pathology using biopsy or surgical material.
In the collection of biopsy specimens for an initial diagnosis of prostate cancer,
sampling variables often play a part. Sampling variables result mainly from the lack of
accurate imaging techniques to identify and sample specific lesions. Thus, while
ultrasound guidance allows for systematic sampling of the prostate, small tumors can be
missed, especially in large hypertrophic prostates. Once sampled, each core is
completely embedded in paraffin, however, the detection rate is affected by analytical
variables such as the number of cores embedded in each block [241] and the number of
sections prepared from each block. The blocks are not serially and completely sectioned
to exhaustion, and thus some tissue remains unexamined in the paraffin blocks. In
addition, differing thresholds for atypical lesions, assessment of Gleason score, and
diagnosis of small cancers are also sources of analytical variability. Second-opinion
reviews suggest that reclassification of a malignant to benign lesion occurs in 1-2% of
cases and in up to 10% of cases a change in Gleason score affecting clinical decision
making may occur [242, 243]. The use of MALDI-IMS may aid the pathologist in these
cases. To that end, we have begun using UMFix to process prostate biopsy specimens in
close collaboration with the pathology group at Sentara Norfolk General Hospital. The
future MALDI-IMS analysis of these tissues will enable us to determine if both the
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expression profile and normalized intensity of m/z 4355 will be useful clinically for the
diagnosis of PCa.
The most helpful utility of this technology could be in the assessment of biopsy
specimens for the prognosis of metastatic disease. Radical prostatectomy when
performed on individuals with metastatic disease is contraindicated due to the over-riding
need for systemic therapy. Removal of the primary tumor has no clear accepted
advantage for survival following the indication of extracapsular metastatic disease, and
can result in potentially adverse surgical complications [75]. Typically, individuals
suffer from impotence, incontinence and urinary obstruction to varying degrees of
severity. Thus, if metastatic disease were to be identified, radical prostatectomy would
not be performed. Our future studies will include a larger cohort of metastatic patients
and the examination of biopsy specimens from patients who later develop metastatic
disease. These types of tissue will be invaluable for the determination of a specific
prognostic protein expression profile determined at the time of biopsy, or after
prostatectomy.
It is clear from our study that better methods of data analysis are needed for the
interpretation and processing of MALDI-IMS data. The exportation of spectra from
regions of interest defined for each tissue examined requires thousands of spectra to be
imported into other programs for analysis. The software package available to us (ClinProt
tools) was inadequate in that each analysis (peak finding and algorithm generation) took
up to 48 hours of computer run-time. Additionally, the handling of such data needs to be
refined in such a way that each ROI is treated as a group and not individual spectra. The
use of genetic algorithms for the classification of our data yielded high sensitivity, but
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low specificity in both PCa vs. Benign, as well as metastatic case vs. control. Clearly
better models are needed. We are currently consulting with computer analysis specialists
in the development of improved software packages for data handling and model
generation in MALDI-IMS.

6.3 AIM 2: Sequence identification and characterization of potential biomarkers for
clinical diagnostics.
A. The identification of the most discriminatory ion overexpressed in PCa tissues has
enabled us to further characterize the molecular landscape of prostate tumors. This ion
peak (m/z 4355) was identified as a fragment of MEKK2. This identification was
achieved using a WCX fractioned bulk tissue lysate. After confirmation of the spectral
patterns in PCa vs. benign lysates, the m/z 4355 ion was sequenced using high mass LIFT
MS/MS.

B. The use of trypsin digestion directly on tissue sections confirmed the presence of
MEKK2 specific peptides in PCa tissue. These peptides were not detected from benign
tissue or control PCa tissue without trypsin treatment. In addition, "in situ" trypsin
digestion also enabled the sequence identification of several other molecules present in
both benign and tumor tissue. Most of the molecules identified were high abundant
proteins, however two molecules sequenced (transgelin and prokineticin-1) are less
abundant proteins and indicate that this method could be useful in the sequence
identification of disease relates proteins or peptides directly from tissue sections.
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C. The high expression of MEKK2 was confirmed in PCa tissues via
immunohistochemistry and Western blot. Staining was confined to epithelial cells and
was primarily cytoplasmic. Western blot analysis revealed MEKK2 full length expression
(70KDa) in three prostate cancer cell lines and higher expression was detected in PCa
bulk tissue lysates when compared to benign. The expression level was calculated to be
greater than 4 fold higher in cancer tissues relative to benign tissues.

D. To determine the possible activation of the ERK5 pathway in prostate tissue, we
investigated the expression levels of the downstream partner of MEKK2, MEK5.
Immunohistochemical staining revealed concordant expression of MEK5 and MEKK2,
although the level of expression of the two molecules varied with Gleason grade. MEK5
expression levels appeared to increase with increasing Gleason score. Conversely,
MEKK2 expression levels were higher in well to moderately differentiated tumors and
lower in high grade tumors.

6.4 Future Directions of Aim 2
The main accomplishment of this Aim was the sequence identification of the m/z
4355 peak as a fragment of MEKK2. This was significant due to the fact that ions above
4000 Da are usually very difficult to sequence using the LIFT MS/MS technology. In the
future we hope to further optimize high mass LIFT to enable the identification of
molecules in the range of 4000-6000 Da. Molecules of this size are not readily separated
by SDS-PAGE and will therefore need to be sequenced using tandem MS. We hope to
sequence identify other proteins/peptides found to be differentially expressed in PCa
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tissues. A major focus will be the identification of ions found to be significant in primary
PCa samples from patients harboring micro-metastatic disease. These molecules should
help us determine the molecular pathways activated in more aggressive tumor types.
To further determine the clinical significance of MEKK2 expression, a larger
cohort of samples will be used to examine MEKK2 expression in tissues using IHC. We
have a large bank of formalin-fixed prostate tissues representing all stages and grades. To
this end, since MEKK2 immunostaining of fixed tissues produced high background in
our hands, the conditions will need to be optimized. The analysis of archived samples
with complete pathology and outcome will allow us to pinpoint which type of tissues and
cells overexpress MEKK2 and provide additional clues as to its role in PCa development
and progression. This information will also help with the validation of MEKK2 as a
biomarker for PCa using MALDI-IMS. Other future projects will address the mechanistic
basis for the formation of the MEKK2 fragment in prostate cancer cells. Since the
antibody used in our study recognizes the N-terminal portion of MEKK2 (where the PB-1
domain is located), it should also bind the fragment we detected. At least two other
antibodies to MEKK2 are available commercially which recognize epitopes in the Cterminus. Immunohistochemical staining using these antibodies will help us to determine
if our fragment or the whole protein can be used as a biomarker.
Additional future studies will examine the role of MEKK2 activation with respect
to ERK5 activity and tumor progression. We were unsuccessful in performing Western
blot analysis for ERK5 and MEK5. Therefore, we will evaluate different antibodies for
these experiments. Future investigations into MEKK2 will also be performed at the
transcript level. Using RT-PCR of microdissected prostate cells, we will determine the
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level of MEKK2, MEK5 and ERK5 mRNA in these cell lysates. Finally, the role of
MEKK2 in PCa will be examined in different prostate cancer cell lines with varying
degrees of aggressiveness. Recently, MEKK2 containing plasmids and siRNA have been
made available commercially. Using these tools, we hope to examine the effect of both
MEKK2 over-expression as well as knockdown in prostate cancer cell lines or other
appropriate cell systems.
The identification of proteins directly from tissue sections is a major hurdle in the
area of MALDI-IMS. Our discovery of transgelin and prokineticin-1 in prostate tissues is
compelling. However, these identifications will need to be confirmed and the expression
levels in each tissue will need to be determined. In the future we hope to use the direct
application of trypsin to profile peptides in tissue (reflectron mode MALDI) in a similar
fashion to protein profiling (linear mode MALDI). This will enable us to visualize
peptides from higher molecular weight proteins and hopefully detect more differentially
expressed molecules. We are currently experimenting with different methods to deposit
trypsin on tissue. The manual spotting method will not provide adequate reproducibility
and therefore spraying trypsin on tissue before the spray coating of matrix will be
performed. Several recent studies have examined the use of trypsin digestion and
MALDI-IMS of formalin fixed paraffin embedded tissues (FFPE) [149, 244]. This
method usually involves a procedure of heat induced antigen retrieval in presence of
EDTA followed by on target trypsin hydrolysis [168]. Using our large tissue bank of
FFPE tissues for MALDI peptide profiling should aid in the discovery of new biomarkers
for PCa.

Most patients with metastatic PCa initially respond to androgen ablation therapy.
However, the cancer often recurs as an androgen-independent tumor which is difficult to
treat [41]. Thus, the progression from androgen-dependence to androgen independence is
a critical step in the development of prostate cancer, yet the molecular mechanisms for
this conversion are poorly understood. MAPK signaling pathways have been shown to
regulate steroid receptor activation and localization through receptor phosphorylation
[245]. Using tissue from patients with both AR dependent and AR independent tumors
we hope to examine the expression levels of MEKK2 and its downstream partners.
TArgeted multiplex MS IMaging (TAMSIM) [246] is a new method which
combines IHC and MALD-IMS for imaging multiple candidate antigens simultaneously.
The TAMSIM strategy is based on the indirect detection of a probe via a reporter group
or "Tag-Mass" indicator that is a small molecule of known mass which is easily
detectable using MALDI-MS. This method has been applied in obtaining specific images
of proteins using tagged secondary antibodies [247]. Recent improvements to this
strategy have tagged primary antibodies with second generation photocleavable tags
which are more stable and act as their own matrix [248]. Tagged antibodies specifically
bind to their target protein in the tissue with sensitivity in the fmole range. The tag is
cleaved from the antibody, desorbed with a laser pulse, and sized by MALDI-MS. This
method permits specific analysis of proteins of high or low molecular weight in tissue
sections and the images created by TAMSIM have shown good correlation with classical
IHC. Any antigen for which a suitable antibody exists can potentially be studied and
multiple antigens can be imaged simultaneously. Our future studies will use this strategy
for the detection and quantitation of MEKK2 in prostate tissues.
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6.5 AIM 3: Evaluation of the clinical utility of MALDI-IMS biomarkers
A. The validation of the biomarkers discovered in Aim 1 was partially successful. Using
a genetic algorithm designed with 6 of the most discriminating m/z values, the correct
classification of frozen PCa tissues was 90%, but only 15.8 % of the normal tissues were
classified as benign. This was also the case for UMFixed tissues in which 100% of the
blinded PCa samples were correctly classified, but only 25% of the benign samples were
classified correctly. The classification of blinded samples was much more successful
when using the normalized intensity cut-off value, derived from the ROC analysis, for the
m/z 4355 peak (MEKK2). For the frozen tissue specimens, 80% of PCA tissues and
84.2% of benign tissues were classified correctly. All of the UMFix processed tissue
samples (4 PCa and 4 benign) were classified correctly using the normalized intensity
cut-off.

6.6 Future Directions of Aim 3
Our validation of the biomarkers discovered in Aim 1 and sequenced in Aim2 was
performed on a small cohort of samples collected at EVMS. We will abandon the use of a
genetic algorithm and use other classification methods as well as the normalized intensity
for the m/z ion at 4355. Future studies will evaluate MEKK2 (as detected using MALDIIMS) using a larger cohort (at least 100 from each disease group) of tissues collected
from other institutions as well as other organ sites. These studies will help us determine if
there is sufficient evidence for potential clinical utility of our biomarker(s) to warrant
further investment in true clinical validation study using hundreds or even thousands of
samples.
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If the images produced from MALDI-IMS do not provide enough detail or cannot
be adequately quantitated in a much larger data set, it may ultimately be necessary to
move to IHC for clinical validation. Once other candidate m/z values are sequence
identified, a panel of markers could be used for classification via MALDI-IMS or IHC.
Multicolor images of tissue sections depicting the expression of multiple biomarkers can
then be used diagnostically.
Finally, we will determine if any of the biomarkers discovered and validated in
tissue samples make their way into proximal fluids of serum. Our laboratory is currently
using expressed prostatic secretions (EPS) for the discovery of new biomarkers. EPS is
obtained by prostate massage, which can be performed during a digital rectal examination
or before radical prostatectomy [249]. We will examine the MALDI spectra obtained
from EPS for m/z peaks which match those obtained from MALDI-IMS. Sequence
identification of these peaks will determine if the same or similar proteins can be detected
in this proximal fluid allowing for a less invasive screening procedure.

6.7 Concluding Remarks
The goal of proteomic analysis of tissue samples is to determine the overall set of
proteins that are important in normal cellular physiology or altered by a disease process.
There are two basic questions in the field of tissue proteomic studies: (1) can proteomic
alternations in cancer cells be reliably measured in tissue? and (2) do the derived
proteomic signatures correlate with biological state, clinical behavior, or therapeutic

response? Using MALDI-IMS we have successfully answered both of these questions.
Our analysis detected discriminating protein expression differences in PCa tissue as
compared to benign tissue. The work reported here represents the first stage in the
proteomic analysis prostate cancer, revealing a specific aberration in a MAP kinase
cascade. This can be viewed as a small step toward the translation of proteomics into the
realm of clinical diagnostics.
Changes in components of critical signaling cascades produce a diversity of
disease states, depending on the specific tissues in which they are disrupted. Moreover,
changes in different components may ultimately lead to common clinical manifestations
reflecting a final common pathway to disease. Once identified and their role in disease
defined, the ability to disrupt a specific signaling function and, thereby, interrupt the
molecular mechanisms underlying pathology becomes a primary focus for individualized
disease management. This practice is already in use today in the treatment of some
tumors. For example, MAPK kinase targeted therapy is the focus of cancer drugs such as
Gleevec (Imatinib), and Iressa [250]. Molecular profiling (genetic and proteomic) may
someday augment and customize a histological diagnosis with the equivalent of a circuit
diagram of altered genes and protein signaling pathways for a patient's tumor. This
functional map of a patient's tumor cells will then become the starting point for
individualized molecular therapy. In the same fashion, proteomic analysis could also be
used to monitor the individual's response to that therapy. In oncology, there are many
proofs of principle for personalized medicine, and many more are emerging. Although
much of its promise remains unproven to date, the foundations of personalized medicine
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appear solid and evidence is accumulating rapidly pointing to its growing importance in
clinical care.
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